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Abstract 
 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central 
nervous system that causes a range of neurological deficits expressed in a series of 
relapses separated by remissions.  Surprisingly, our understanding of the mechanisms 
responsible for both relapses and remissions remains incomplete, even for the 
expression of major deficits.   
 
To explore the mechanisms, a model of MS (experimental autoimmune 
encephalomyelitis, EAE) has been studied neurologically, electrophysiologically and 
histologically at five time points along the course of the disease, i.e., 'preinduction', 
'predisease, 'peak disease', 'remission', and 'relapse'.  The animals were assessed daily 
to determine the magnitude of any neurological deficit, and electrophysiological 
techniques were developed to permit serial measures of axonal conduction, synaptic 
transmission, and the excitability of motor neurons.  Also, to investigate whether 
inflammatory factors can modulate the expression of neurological deficits, a pro-
inflammatory agent, lipopolysaccharide (LPS) was injected systemically in animals at 
the ‘remission’ phase to explore whether systemic inflammation exacerbates the 
disease.  A selective inhibitor of inducible nitric oxide synthase (iNOS), 1400W, was 
also administered into animals with EAE at the onset of disease expression to examine 
whether inhibition of nitric oxide (NO) production ameliorates the disease. 
 
The findings have revealed that no electrophysiological deficits were detected before 
the onset of neurological deficits, but axonal conduction and synaptic transmission 
were significantly impaired at the ‘peak disease’.  These measures remained reduced 
during the ‘remission’ and ‘relapse’, at which time motor neuronal excitability was 
also significantly decreased.  It is intriguing that none of the electrophysiological 
measures have so far revealed changes that correlate closely with the expression of, 
and recovery from, neurological deficit.   
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Present data also show that systemic inflammation induced by an injection of LPS in 
animals with EAE caused an acute relapse that peaked 3.5 hours post injection.  
However, no electrophysiological changes occurring at this peak were detected that 
could be responsible for the transient neurological deficits, and so the exact 
mechanisms underlying the deficits remain unknown.  Also, based on the histological 
analysis revealing an exclusive expression of iNOS at ‘peak disease’ in animals with 
EAE, the consequences of selective inhibition of iNOS using 1400W were explored.  
This treatment significantly reduced the severity of the neurological deficits, 
implicating NO in their production.  Importantly, electrophysiological and histological 
examination of 1400W-treated animals revealed that the inhibition of iNOS also 
provided significant protection from the loss of function, and degeneration, of axons, 
again implicating NO in a pathogenic role.   
 
In conclusion, these findings add further weight to the evidence that inflammation 
plays a key role in the pathogenesis of EAE, although the exact mechanisms 
underlying the production of the neurological deficits remain unknown.  Potential 
explanations are discussed, including the possibility that the deficits may arise from 
spinal hypoxia.  In addition, the inhibition of NO production may provide an effective 
protection from both the functional and pathological consequences of 
neuroinflammatory diseases such as MS.   
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Chapter 1.  Introduction 
1.1.  Multiple sclerosis (MS) 
 
Multiple sclerosis (MS) is a disease of the central nervous system, characterised by 
inflammation, demyelination and axonal degeneration.  It is the most common 
disabling neurological disease among young adults and it affects around 85,000 people 
in the UK and approximately 2.5 million people between 17 and 65 years old 
worldwide, with an incidence of approximately 7 new cases per 100,000 person years 
at risk (Compston and Coles 2002;Kantarci and Wingerchuk 2006).  Many attempts 
have been made to identify the cause of MS, and to date, a number of complex genetic, 
environmental factors have been suggested to be involved.  Among the genetic factors, 
MHC class II genes have been reported to be strongly involved (Ramagopalan et al. 
2009), which was amongst the earliest studied in the field of MS genetics.  
Environmental factors related to MS include gender (Eikelenboom et al. 2009), 
vitamin D intake (Solomon and Whitham 2010), and viral infections (Lipton et al. 
2007).   
 
1.1.1.  Clinical manifestations and disease course of MS 
 
MS is a chronic debilitating disease that reduces the lifespan by an average of seven to 
eight years (Trapp and Nave 2008), and the clinical symptoms and disease course are 
widely variable.  The common clinical symptoms involved are loss of vision, motor 
weakness, sensory loss, gait impairment, cognitive impairment, bladder dysfunction, 
mood disorders, sexual dysfunction, pain and fatigue (Boissy and Cohen 2007).  In 
1996 the terminology used to describe the pattern and course of MS was standardised 
under the auspices of the National Multiple Sclerosis Society of the USA (Lublin and 
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Reingold 1996), which classified the disease course in four different categories.  These 
categories are described below. 
 
1)   Relapsing-remitting (RR) MS : clearly defined disease relapses with full 
recovery or with sequelae and residual deficit upon recovery; periods between disease 
relapses characterised by a lack of disease progression.  
2)   Primary-progressive (PP) MS : disease progression from onset with occasional 
plateaus and temporary minor improvements allowed. 
3)   Secondary-progressive (SP) MS : initial RR disease course followed by 
progression with or without occasional relapses, minor remissions, and plateaus. 
4)   Progressive-relapsing (RP) MS : progressive disease from onset, with clear acute 
relapses, with or without full recovery; periods between relapses characterised by 
continuing progression. 
 
Approximately 15% of MS patients experience a primary-progressive (PP) disease 
course, and 85% exhibit a relapsing-remitting (RR) disease course, later going through 
periodic exacerbations and entering the progressive phase (Compston and Coles 2002).  
As relapse and remissions have been the characteristic features of MS, they have long 
been used as a tool to study the aetiology and pathogenesis of MS, and to assess the 
therapeutic efficacy of potential treatments.  However, the exact cause and 
mechanisms underlying the disease phases are not fully understood.  The next section 
describes the potential mechanisms responsible for relapse and remissions in MS and 
EAE that have been reported so far. 
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1.1.2.  Possible mechanisms of relapse and remissions in MS 
 
1.1.2.1.  Mechanisms of relapse 
 
The types and duration of symptoms that MS patients experience from the occurrence 
of relapses are heterogeneous.  The reason for this heterogeneity is not fully revealed, 
but it may be due to a combination of different pathological events ranging from 
infection, psychological stress, molecular characteristics, inflammation, and 
demyelination.   
 
Infection 
 
A number of studies have suggested the association of clinical symptoms and viral or 
bacterial infections (Edwards et al. 1998;Confavreux 2002;Giovannoni et al. 2006).  
The authors generally propose that relapse can occur through epitope mimicry between 
microbial and self-antigens inducing the activation of the immune system, followed by 
migration of immune cells into the CNS.  These cells such as blood-born mononuclear 
cells and autoreactive T cells secrete inflammatory cytokines and inflammatory 
mediators which contribute to local inflammation.  Secondary effects such as fever 
from the infection have also been found to induce pseudo-relapse.  This has been 
reported both clinically (described as Uhthoff’s phenomenon (Uhthoff 1890)) and 
experimentally, that hyperthermia may exacerbate the symptoms by causing 
conduction block in peripheral and central axons (Davis and Jacobson 1971;Bajada et 
al. 1980;Pender and Sears 1984).   
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 Stress 
 
The description of the potential link between stress and MS symptoms was first made 
by Charcot (Charcot JM 1877) who noted that grief, vexation and changes in social 
circumstances may relate to exacerbations.  More recently, a number of studies have 
appeared reporting a positive correlation between psychological stress and symptoms 
(Rabins et al. 1986;Mohr et al. 2004;Artemiadis et al. 2011).  A systematic and 
quantitative meta-analysis performed by Mohr et al, reported a consistent association 
suggesting that stress management may be of therapeutic value (Mohr et al. 2004).  
However, controversies have arisen due to the uncertain nature of any biological 
mechanisms, and due to the variability in measurement of stress, both of which 
encourage limitations in interpreting the results.  Indeed, a recent study from Riise et al 
(Riise et al. 2011) reported that there was no increased risk of MS associated with 
severe stress.  At present, further analyses are required to explore whether stress causes 
relapses in patients with MS and, if so, research is needed to determine the 
mechanisms involved. 
 
Molecular characteristics 
 
Recent studies employing molecular biological techniques have improved our 
knowledge of MS pathophysiology.  The molecular characteristics of MS may be used 
as biomarkers for predicting the onset and duration of relapses, and may also help 
selecting the accurate therapeutical interventions.  MHC class II genes (Ramagopalan 
et al. 2009) and IL-7 receptor (Lundmark et al. 2007) genes have been found to be 
associated with higher risk of developing MS.  Also, a molecular trio has been 
reported which explains the mechanism behind relapse and remissions.  The binding of 
α4β1 integrin on T lymphocytes with osteopontin expressed on inflamed endothelium 
induces relapses by stimulating the expression of pro-inflammatory cytokines (Chabas 
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et al. 2001;Jansson et al. 2002) and by inhibition of apoptosis of autoreactive immune 
cells (Hur et al. 2007).  However, αB crystallin is the molecule that acts as a chaperone 
to this pair, which inhibits NF- κB mediated transcription of pro-inflammatory 
cytokines therefore contributing to remission (Ousman et al. 2007).   
 
Inflammation 
 
A number of clinical studies reported the key role of inflammation in causing deficits.  
Youl and others found that the leakage of Gd-DTPA was associated with exacerbation 
of clinical symptoms such as abnormal visual acuity and reduction of the visual 
evoked potentials in patients with optic neuritis (Youl et al. 1991).  The role of 
cytokines such as TNF-α and IFN-γ have also been reported in patients with MS as the 
increased levels correlated with significant worsening of the symptoms or re-
awakening of pre-existing symptoms  (Moreau et al. 1996).  In addition,  although 
axonal injury was generally considered to be a sequel of demyelination, it was reported 
that axonal injury could be mediated by inflammatory cells such as macrophages, 
microglia, and CD8 + T lymphocytes, independent of demyelination  from autopsy 
tissues of MS patients (Bitsch et al. 2000).   
 
The exact mechanisms of the neurological deficits induced by inflammation remain 
speculative, but it has been generally accepted that the autoreactive T lymphocytes and 
their soluble mediators play an important role in the pathogenesis of MS.  Infiltration 
of these T lymphocytes occurs in MS lesions through penetration of the blood-brain 
barrier (BBB) and mediates damage of the myelin sheaths.  These cells may also be 
responsible for axonal injury (Booss et al. 1983;Bitsch et al. 2000;Fletcher et al. 2010), 
and CD8+ T lymphocytes have been implicated in the production of neurological 
deficits via mechanisms involving perforin (Murray et al. 1998;Friese and Fugger 
2009).  The cytokines produced by the T cells such as  TNF-α and IFN-γ may also 
induce the production of a powerful inflammatory mediator, inducible nitric oxide 
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synthase (iNOS), for which a role has been implied in impairing neurological functions 
in both MS and EAE (MacMicking et al. 1992;Bo et al. 1994;Willenborg et al. 2007).  
It has been reported that increased level of nitric oxide (NO) produced by its induced 
synthase may cause axonal degeneration at physiological frequencies of impulse 
conduction (Smith et al. 2001), and also that it has an effect on the sodium and 
potassium channels  upon which conduction depends (Ahern et al. 1999;Ahern et al. 
2000).  Furthermore, mitochondrial activity can also be impaired by NO, which could 
lead to lack of ATP in axons preventing them from maintaining their normal functions 
(Bolanos et al. 1997).  Further detailed role of NO in lesions of MS and EAE are 
described in a later section.   
 
Synaptic dysfunction 
 
Inflammation has also been reported to affect synaptic transmission, causing impaired 
function in the grey matter.  Several factors including IL-2 (Park et al. 1995), TNF-α 
(Tancredi et al. 1992), IFN-γ (D'Arcangelo et al. 1991) and especially NO were 
reported to disturb synaptic transmission in the grey matter (Fossier et al. 1999), which 
may lead to axonal degeneration in combination with impaired sodium channels 
(Smith 2007), NMDA receptors (Piani et al. 1991), and raised glutamate release (Pitt 
et al. 2000). 
 
Demyelination 
 
Demyelination is a hallmark of MS pathology, which is the most well known cause of 
conduction block responsible for the neurological deficits.  Demyelination can happen 
segmentally, when the myelin is lost between the two adjacent nodes (i.e. segmental 
demyelination), or by nodal widening occurring from the loss of myelin from the 
paranodes (Waxman 1989;Smith and Hall 2001;Wolswijk and Balesar 2003).   This 
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conduction failure is due to lack of sodium channels in the exposed axolemma, as the 
density of the channels is much lower for normal conduction (Waxman 1989;Waxman 
and Ritchie 1993).  In addition, it has been reported that demyelinated axons have a 
low safety factor for conduction (near 1 in demyelinated axons, whereas in normal 
myelinated axons it is around 3-5) (Smith 1994).  This implies that any subtle changes 
to the environment which might affect the safety factor such as temperature (Davis 
1970) can hinder normal conduction.  
 
1.1.2.2.  Mechanisms of remission 
 
Remission occurs in patients with MS for variable time periods, often followed by 
another relapse.  This remission may occur by means of counterbalancing some of the 
factors listed above, such as through remyelination or resolution of inflammation.  
Remyelination occurs in response to demyelination by the recruitment of 
oligodendrocyte precursor cells (Sim et al. 2002), where these cells restore myelin 
sheaths engaging the axon (Watanabe et al. 2002), and enabling recovery of saltatory 
conduction of action potentials (Smith et al. 1979;Nave and Trapp 2008).  However, 
this restoration of conduction may also occur in the absence of remyelination, when 
new sodium channels appear in the denuded axons.  It has been reported that 
aggregations of sodium channels were found along the demyelinated axolemma 
enabling slow conduction (Black et al. 1991;Felts et al. 1997).  The appearance of 
sodium channels has also been found in astrocytes in lesions, which may support 
Na+/K+ ATPase-dependent ionic homeostasis in areas of injury (Black et al. 2010). 
 
On the other hand, resolution of inflammation within the lesions can also influence the 
recovery in patients as reported by Youl and others (Youl et al. 1991).  They have 
found that clinical recovery was associated with the cessation of leakage across the 
blood- optic nerve barrier.  Also, the resolution of inflammatory mediators such as NO 
was found to reverse blocked conduction within experimentally demyelinated axons 
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(Redford et al. 1997).   
Furthermore, adaptive changes in the cerebral cortex may contribute to the recovery of 
symptoms evidenced by fMRI studies in MS patients (Pantano et al. 2006;Cerasa et al. 
2006).  These adaptive changes could be comparable to cortical reorganisation 
occurring as a consequence of a CNS injury, by strengthened synaptic connections or 
regulation of neurotransmitters and their receptors (Endo et al. 2009). 
1.2.  Experimental autoimmune encephalomyelitis (EAE) 
 
Animal models of multiple sclerosis are indispensable for understanding the aetiology 
and pathology of the disease, as there is limited access to human tissue from MS 
patients.  The animal models reflect the different clinical courses and pathology of MS, 
depending on the method of disease induction.  One common method is employing 
viral infection, based on the ground that viral infection plays an instrumental role in 
the development of CNS autoimmunity.  For example, Theiler’s murine 
encephalomyelitis virus and corona virus infect and damage oligodendrocytes resulting 
in destruction of myelin (Grigoriadis and Hadjigeorgiou 2006).  Alternatively, 
neurotoxicants such as cuprizone have been used to induce demyelination by oral 
administration (Blakemore 1972;Matsushima and Morell 2001), to produce central 
demyelinating lesions.  However, experimental autoimmune encephalomyelitis (EAE) 
is so far the most intensively studied models of MS that can be produced by active 
sensitization to particular tissue or protein components of the central nervous system, 
or by passive transfer of autoreactive T cells (Stromnes and Goverman 2006).  The 
characteristics of the disease induced rely on the type of antigen used for sensitization, 
and the species or the strain of the animal used.  The first actively induced EAE was 
developed in 1933 when Rivers et al. showed EAE was induced in primates when 
immunized with normal rabbit brain tissue (Rivers 1933).  Additionally, the passively 
induced EAE model was developed subsequently in 1960 by transfer of lymph node 
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cells from rats immunised with spinal cord homogenates into naïve animals (Paterson 
1960). 
  
There are a number of types of EAE which reflect the heterogeneous pathology of MS 
depending on the method of induction (active or passive), type of antigen used for 
sensitization (e.g. myelin basic protein (MBP), proteolipid protein (PLP), and myelin 
oligodendrocyte protein (MOG) (Muller et al. 2000)), and the type of animal/strain 
used.  Depending on these factors, animals express different types of neurological 
deficits.  The classic neurological deficits are expressed by ascending flaccid paralysis, 
presented as having a flaccid tail leading to paralysed limbs (Stromnes and Goverman 
2006).  However, while a number of experimental models present an acute disease 
course, fewer models show a chronic progressive or relapsing pattern (Skundric 2005).   
 
1.2.1.  Relapsing-remitting EAE 
 
Relapsing-remitting EAE is a useful model employed for understanding the aetiology 
and pathology of multiple sclerosis, as a high proportion of patients suffer from this 
relapsing form.  However, the exact mechanisms causing the different stages of the 
disease are not clearly understood.  
  
Recent research has elucidated a number of mechanisms underlying the relapses using 
various models of EAE exhibiting a relapsing remitting form (Skundric 2005).  The 
role of mononuclear cells has been reported in EAE, that the reappearance of these 
cells was associated with relapses (Bjartmar and Trapp 2003).  Furthermore, 
convincing evidence in EAE has demonstrated that the occurrence of epitope 
spreading also contributes to relapses, resulting from increased immune reactivity 
against an expanding array of myelin target epitopes (Tuohy et al. 1998;Miller and 
Eagar 2001;Steinman 2004).  Also the role of chemoattractants such as chemokines or 
cytokines was implicated in the relapsing disease, inducing further inflammatory 
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attacks (Imitola et al. 2005;Engelhardt 2008).  Macrophage chemoattractant protein-1 
(MCP-1) which belongs to a CC family of chemokines regulates the influx of 
macrophages and memory T cells into the CNS (Mahad and Ransohoff 2003).   It has 
been shown that the expression of MCP-1 correlated with the severity of the disease in 
EAE, and when these animals were treated with anti-MCP-1 antibodies the relapse rate 
was significantly reduced (Karpus and Kennedy 1997).  Others reported the regulatory 
role of IL-16, a CD4+ T cell chemoattractant cytokine in the pathogenesis of EAE.  
The level of IL-16 in the CNS correlated positively with the number of infiltrating 
CD4+ and CD8+ T cells during the relapses, and animals that were treated with anti-
IL-16 antibodies showed amelioration of the neurological deficits (Skundric et al. 
2005).   
 
1.2.2.  rMOG-EAE induced in DA rats 
 
Myelin oligodendrocyte glycoprotein (MOG) is a type I membrane glycoprotein 
exclusively expressed in the CNS (Linington and Lassmann 1987), which induces a 
type of EAE in animals when injected as an emulsion with an adjuvant.  MOG is 
highly conserved between species including human, rat, mouse, and bovine species 
(Hilton et al. 1995), and it has been reported that the pathology occurring as a 
consequence of an injection of MOG in DA rats closely resembles PatternⅡ lesions, 
which are arguably the most frequent type of MS lesions (Storch et al. 1998;Schubart 
A 2001).  The lesions are characterised by infiltration of autoimmune T and B 
lymphocytes, perivenous phagocytic cells, widespread demyelination and relative 
sparing of axons, in the context of complement binding.  Not only are the lesions 
similar to MS, but the incidence of the disease in DA rats is very high (95.28%) and 
reproducible (Storch et al. 1998).  The rats can exhibit a chronic disease course, 
making the model an attractive tool for studying the mechanisms of relapsing-
remitting MS: for these reasons the model was chosen for the present study.  Although 
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the exact pathomechanisms responsible for the disease expression in this model remain 
to be elucidated, it has been reported that the first peak of disease may be driven by 
inflammation mainly by autoimmune CD4+ Th1 cells which induce the recruitment 
and activation of ED1+ macrophages.  MOG-specific autoantibodies have been 
attributed as the driving force for inducing demyelination in the relapses during the 
progressive phase of the disease (Schubart A 2001).  
 
1.3.  Electrophysiological studies in EAE 
 
In comparison with the number of studies on EAE (8348 articles in Pubmed), 
relatively few (only 13) have examined the disease electrophysiologically.  Indeed few 
investigators appear to have wondered why the animals have a neurological deficit, 
and the assumption appears to have been that the deficits are due to demyelination.  
Prior to these electrophysiological investigations, it was widely believed that 
neurological deficits in EAE, such as tail or hindlimb weakness, were due to CNS 
lesions similar to MS.  However, whilst chronic relapsing models of EAE showed 
large plaques of demyelination in the CNS, such plaques were rare or absent in acute 
EAE.  It was hypothesised that the cause of neurological deficits in these animals were 
due to other factors such as oedema (Paterson 1976), or an impairment of 
monoaminergic neurotransmission (Carnegie 1971).  However, histological evidence 
had challenged this hypothesis by reporting pathology in the PNS of acute EAE 
animals (WAKSMAN and ADAMS 1955).  In light of these evidences, Pender et al 
conducted studies investigating the cause of neurological deficits and found evidence 
indicating that the conduction block was due to demyelination occurring in both the 
CNS and PNS.  The reported sites of predilection for demyelination in the CNS were 
the dorsal root entry zones and the ventral root exit zones.  In the PNS, the dorsal root 
ganglia and spinal roots were frequently affected. 
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The studies were conducted in rabbits (Pender and Sears 1982;Pender and Sears 1984) 
and Lewis rats (Pender and Sears 1986;Pender 1986a;Pender 1986b;Pender 
1988a;Pender 1988b;Pender 1989;Stanley and Pender 1991;Deguchi et al. 1992;Chalk 
et al. 1994;Chalk et al. 1995) either inoculated with whole spinal cord, MBP or PLP to 
induce EAE.  In the rabbits and rats inoculated with whole spinal cord to induce EAE, 
demyelination of the dorsal root ganglia and the dorsal root entry zone were suggested 
as the cause of conduction block (Pender and Sears 1982;Pender and Sears 
1984;Pender and Sears 1986;Pender 1986a;Pender 1988b).  In these rats the ventral 
root exit zones were also reported to be a site for demyelination (Pender 1986b).  In 
the rats with EAE induced by inoculation with MBP, demyelination and nerve 
conduction abnormalities were demonstrated in the dorsal roots, dorsal root entry 
zones, ventral roots and ventral root exit zones (Pender 1986a;Pender 1988b;Pender 
1989).  Additionally a study on passively induced EAE in rats by transferring T 
lymphocytes activated against MBP showed that the impaired conduction was due to 
the slowing of afferent conduction within the dorsal column and spinal roots from 
demyelination (Heininger et al. 1989).  On the other hand, in animals with PLP-
induced EAE, the demyelination induced conduction block was restricted to the CNS 
which implies that PLP or other antigen confined to the CNS such as MOG could be 
the target antigen in MS (Chalk et al. 1994).  In addition to these studies suggesting the 
cause of neurological deficits, the mechanism of clinical recovery in animals with 
acute EAE and chronic relapsing EAE was explained by remyelination in both CNS 
and PNS, by oligodendrocytes and Schwann cells respectively (Pender 1989;Stanley 
and Pender 1991).  Notably, the incomplete recovery of conduction block in the 
chronic relapsing EAE animals exhibited at late remission were attributed to axonal 
degeneration (Stanley and Pender 1991). 
 
Various electrophysiological methods were used in these studies to investigate the 
cause of neurological deficits.  Recordings from the ‘volume conductor’ were used to 
reveal the site of axonal conduction block in some studies (Pender and Sears 
1982;Pender and Sears 1984;Pender and Sears 1986;Pender 1986a;Pender 
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1986b;Pender 1988a;Pender 1988b;Pender 1989;Stanley and Pender 1991), and the 
monosynaptic reflex pathway was examined by recordings of the H reflex (Pender 
1987;Pender 1988a;Pender 1989;Stanley and Pender 1991).  Furthermore, to 
investigate the afferent conduction pathways, recordings were made of the spinal cord 
dorsal column compound action potential (Stanley and Pender 1991;Chalk et al. 
1994;Chalk et al. 1995) and the cerebral cortical somatosensory potential, typically 
evoked by stimulation of the sciatic nerve (Deguchi et al. 1992).   
In summary, these studies concluded that demyelination occurring both in the CNS 
and PNS is the main cause of the neurological deficits.  This belief was further 
supported by observations that the axons had impaired ability to transmit trains of 
impulses and were susceptible to temperature changes, namely characteristics of 
demyelinated axons (Stanley and Pender 1991).  
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1.4.  Nitric oxide (NO) in MS/EAE and implications for therapy 
 
1.4.1. Nitric oxide (NO) and its dual role 
 
Nitric oxide (NO) is a free radical, inorganic gas produced by the oxidation of the 
terminal guanidine nitrogen of arginine, and catalysed by an NADPH dependent 
enzyme, nitric oxide synthase (NOS) (Stuehr and Marletta 1987).  It is produced in 
many types of cells in the body (Marletta 1993), and has been implicated in a variety 
of inflammatory mediated disorders occurring in the joint, gut, lung and brain 
(Moncada and Higgs 2006;Sharma et al. 2007).  Under normal physiological 
conditions, neuronal cells and endothelial cells produce NO by neuronal NOS (nNOS 
or NOS1) and endothelial NOS (eNOS or NOS3) respectively, which are 
constitutively expressed and activated in response to intracellular calcium/calmodulin 
levels (Bredt and Snyder 1990).  NO produced by nNOS acts as a neurotransmitter 
(Stuehr and Marletta 1987), whereas eNOS-derived NO regulates vascular tone 
(Ignarro 1989), adhesion of circulating blood cells and inhibits platelet aggregation 
(Kubes et al. 1991).  In abnormal conditions however, such as in response to 
inflammatory stimuli for instance cytokines or lipopolysaccharide, the inducible 
isoform of NOS (iNOS or NOS2) is expressed in many cell types including 
macrophages, microglia, neutrophils, and it produces the NO in a calcium-independent 
manner, producing NO in large quantities (Salter et al. 1991).  
 
Several reports suggest that NO may possess a dual role; a destructive or a protective 
role in an inflammatory environment.  One study that supports the ‘destructive’ role of 
NO described that NO could down-regulate the synthesis of IL-6, yet up-regulate the 
production of TNFa in a macrophage cell line, exerting cytotoxic action on the cells, 
which may contribute to tissue destruction (Deakin et al. 1995).  NO itself does not 
only act as a reactive radical, but also reacts with superoxide anion (O2•-) to generate 
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the peroxynitrite anion (ONOO-), which is an even stronger oxidant (Beckman et al. 
1990).  Also, NO derived from activated microglia and astrocytes has been implicated 
in the damage of myelin-producing oligodendrocytes (Merrill et al. 1993;Koprowski et 
al. 1993) in EAE models.  Furthermore, in MS patients NO has been reported to affect 
the integrity of the blood-brain barrier (BBB) as the nitrite and nitrate concentrations 
in the cerebrospinal fluid correlated with BBB breakdown (Giovannoni 1998).  NO has 
also been demonstrated to cause vasodilation which may also assist the inflammatory 
process (Xiao et al. 1996).  
  
On the contrary, the ‘protective’ role of NO was introduced from reports showing that 
NO down-regulates immune responses by suppressing Ia expression of activated 
macrophages (Sicher et al. 1994), where increased expression of Ia molecules has been 
reported in EAE (Stoll et al. 1993).  Moreover, NO produced by macrophages has been 
shown to inhibit lymphocyte (Denham and Rowland 1992), and also to inhibit the 
adhesion of leucocytes to the vascular endothelium (Kubes et al. 1991).  The dual roles 
of NO described so far suggest that experiments which aim to explore the role of NO 
using inhibitors of nitric oxide synthases (NOS) may provide complex results.  
 
1.4.2.  Nitric oxide (NO) in MS 
 
The presence of NO and induction of iNOS have been reported in the inflammatory 
demyelinating plaques of patients with MS.  Bo et al demonstrated NADPH 
diaphorase histochemical staining in the brains of MS patients, and also concluded that 
the majority of these cells which produced NO were astrocytes since these cells 
showed immunoreactivity to glial fibrillary acidic protein (GFAP) (Bo et al. 1994).  
Furthermore, they showed that levels of iNOS mRNA were significantly higher in 
patients’ brain with MS compared to control groups.  Another group reported that 
nitrated proteins in MS lesions co-localised with mRNA of iNOS in macrophages or 
microglia (Bagasra et al. 1995).  This finding suggests that not only NO exists in these 
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lesions, but also peroxynitrite anion (ONOO-) could be present since protein nitration 
was observed.  In addition, the presence of NO in patients was also detected by 
examining the concentration of nitrite and nitrate within the CSF (Cross et al. 
1998;Brundin et al. 1999), and from the significantly raised nitrotyrosine levels 
(Zabaleta ME et al. 1998).  
 
1.4.3.  Nitric oxide (NO) in EAE 
 
Numerous studies have attempted to detect the presence of NO or NOS in EAE to 
understand the pathological role of these molecules, and apply the knowledge for 
developing therapy.  Macmicking et al first reported that NO and superoxide anion 
(O2•-) was released from neutrophils and mononuclear cells isolated from Lewis rats 
with acute guinea pig spinal cord homogenate-induced EAE (MacMicking et al. 1992).  
A year afterwards, Koprowski et al. described that iNOS mRNA was found broadly 
along the disease course of EAE in the brains of Lewis rats induced with MBP 
(Koprowski et al. 1993).  Other studies followed, reporting the positive correlation of 
iNOS expression with the severity of neurological signs, in animals induced with EAE.  
For example, in the studies of Van Dam et al, the authors concluded that the altered 
functions of the brain in Lewis rats induced with EAE by guinea pig spinal cord 
homogenate may be due to the infiltration of iNOS positive peripheral macrophages 
(Van Dam et al. 1995).  These cells were detectable at 15 days post induction of EAE 
coinciding with the symptoms such as paresis and paralysis of tail and/or hindlimbs.  
An interesting study by Okuda et al explored the presence of iNOS at different time 
points along the EAE disease course (induced in mice with rabbit MBP), and showed 
that iNOS was most highly expressed at the peak of the disease where animals showed 
severe or complete hindlimb paralysis (Okuda et al. 1995).  Again, the iNOS positive 
cells were mostly macrophages, and the authors suggested that the excessive NO 
production by these cells could be responsible for the damage in the central nervous 
system in EAE.   
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1.4.4.  Nitric oxide (NO) and loss of function 
 
How inflammation impairs function is still not clearly understood, but there is growing 
evidence on the role of NO in the loss of neurological functions.  An interesting study 
from Redford et al reported that NO caused a reversible conduction block in both 
normal and demyelinated axons (Redford et al. 1997), which implies that NO may 
contribute to clinical deficits in inflammatory diseases of the nervous system.  A 
possible mechanism has been suggested, that NO may affect axonal conduction by 
directly impairing the function of axonal channels including sodium channels (Li et al. 
1998;Ahern et al. 2000), potassium channels(Ahern et al. 1999) and calcium channels 
(Kurenny et al. 1994).  NO may also impair conduction by inhibiting the Na+/K+ 
ATPase activity in an autocrine fashion causing depolarisation of the axons (Guzman 
et al. 1995).  In addition, various redox forms of NO can also modify the NMDA 
receptors (Choi and Lipton 2000;Amitai 2010), therefore affecting synaptic 
transmission.  Another role of NO has also been implied in causing axonal 
degeneration, known as a major cause of permanent deficits in MS.  Smith et al 
described that the combination of normal impulse traffic and NO at sites of 
inflammation may cause axonal degeneration, as they observed early stages of 
wallerian degeneration in the dorsal roots stimulated at 50 or 100Hz, exposed to NO 
(Smith et al. 2001).  NO has also been reported in hindering ATP production by 
mitochondria by outcompeting oxygen for binding at cytochrome C oxidase (Cleeter et 
al. 1994;Bolanos et al. 1997;Brown and Borutaite 2002).  This inadequate ATP 
production prevents ATPase pumps, such as the Na+/K+ pump, from working properly, 
which may have a damaging effect on the axons, as it produces intra-axonal Na+ 
accumulation leading to a build up of Ca2+ entry due to Na+/Ca2+ exchanger activity, 
similar to what happens to axons in ischemia (Stys et al. 1991;Waxman et al. 
1994;Lehning et al. 1996;Kapoor et al. 2003).  Furthermore, the peroxynitrite anion 
(ONOO-),  produced from the combination of NO with superoxide anion (O2•-), may 
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induce cytochrome C release from the inter-membrane space causing apoptosis (Su et 
al. 2009).   
 
1.4.5.  Studies using  inhibitors of nitric oxide synthase (NOS) in EAE 
 
Based on the studies suggesting pathological roles of NO, a number of attempts were 
made to treat EAE using NOS inhibitors.  Most of the studies using NOS inhibitors 
were performed during the late 1990s, starting with a study from Cross et al (Cross et 
al. 1994).  They used aminoguanidine (AG) which is a selective iNOS inhibitor in SJL 
mice with adoptively transferred EAE, and showed that AG inhibited the expression of 
disease, suggesting a destructive role of NO.  The use of AG was further proved to 
prevent EAE in adoptively transferred EAE in rats (Zhao et al. 1996) and actively 
induced EAE with MBP in mice (Brenner et al. 1997).  Subsequently more studies 
emerged testing NOS inhibitors in animals with EAE, and the destructive role of NO 
was further supported by the positive correlation of the iNOS expression with the 
disease activity (Van Dam et al. 1995;Cross et al. 1996;Zhao et al. 1996;Brenner et al. 
1997).  Furthermore, nitrotyrosine, which is a marker for peroxynitrite-induced 
damage was detected in mononuclear inflammatory cells and CD4+ T cells in adoptive 
EAE in mice (van, V et al. 1997), and was also found to correlate with the peak of 
disease in the spinal cord lesions of mice with EAE (Okuda et al. 1997). 
  
However, a study conducted by Zielasek et al reported that no amelioration of the 
disease was found using different types of NOS inhibitors such as AG, N-
monomethylarginine (NMMA), N-nitroarginine (NNA), and in fact even that such 
therapy could exacerbate the neurological deficits in Lewis rats induced with MBP-
EAE (Zielasek et al. 1995).  It was suggested for the first time from this study that NO 
may possess a complex role in EAE.  Another study using a non-selective NOS 
inhibitor N-nitro-L-arginine-methylester (L-NAME) and N-monomethyl-L-arginine 
(NMMA) in active EAE in Lewis rats, reported that the therapy aggravated the 
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neurological deficits, and supported an immunosuppressive role of NO in the disease 
process (Ruuls et al. 1996).  In addition, iNOS knockout (-/-) mice with EAE were 
reported to show greater incidence and higher neurological scores than the wild type 
controls, and also were less able to recover from the deficits (only 19% of iNOS -/- 
mice had recovered compared with 82% of wild type animals) (Fenyk-Melody et al. 
1998). 
   
So far many authors speculated that the contradicting outcomes of the studies using 
NOS inhibitors in EAE may be due to the use of different methods of EAE induction, 
the type of the inhibitor, different administration routes and dosing schedules of the 
inhibitors.  Indeed a paper from Okuda et al reported that the timing of treatment using 
AG in mice with active EAE at different times along the disease course of EAE can be 
crucial (Okuda et al. 1998).  The administration of AG from day 2 to day 12 after 
immunization caused a significant delay in the onset of EAE, but administration for 10 
days after the onset of EAE enhanced both the neurological deficits and the mortality 
rate, and also accelerated the onset of relapse significantly.  The authors concluded that 
NO is a pathogenic factor in the induction phase but has an inhibitory role in the 
progression phase, and suggested that timing should be taken into consideration in 
designing treatments in both EAE and MS.  Moreover, a few studies have suggested 
that the amount of NO that can be produced varies between strains or genders of 
animals, and this could influence the susceptibility of the disease and may explain the 
contradictory outcomes of experiments using NOS inhibitors.  Cowden et al described 
that PVG rats, which have low susceptibility to EAE, had significantly increased 
serum NO levels after the induction of MBP-EAE, compared with Lewis rats (Cowden 
et al. 1998).  When the PVG rats were treated with N-methyl-L-arginine (L-NMA) a 
NOS inhibitor, the rats acquired high susceptibility to EAE and showed decreased NO 
levels.  Hence the authors reported a protective role of NO, as the lymph node cells 
isolated from the inhibitor-treated PVG rats with EAE showed higher proliferation rate 
than the controls.  This finding implies that NO may down-regulate EAE by inhibition 
of T cell proliferation.  On the contrary, female SJL/J mice expressed higher levels of 
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NO and developed more severe EAE compared with males, suggesting a destructive 
role of NO in the pathogenesis of EAE (Ding et al. 1997).   
Altogether these studies imply that more intensive studies on the role of NO are 
required to understand the exact mechanisms underlying the disease course of EAE 
and are indispensable for future application of therapy in patients with MS. 
 
•  1400W, a selective inhibitor of iNOS 
 
1400W dihydrochloride [N-(3-(Aminomethyl)benzyl)acetamidine.2HCl] identified by 
Garvey et al, is a highly selective iNOS inhibitor versus both eNOS (greater than 5000 
fold) and nNOS (greater than 200 fold) in both human and rats (Garvey et al. 1997).  
1400W inhibits NOS by binding at the arginine-binding site in competition with L-
arginine (Alderton et al. 2001).  It has been reported that no reversal of inhibition 
occurred after two hours of injection; hence 1400W is either irreversible or only very 
slowly reversible (Garvey et al. 1997).  1400W has been used in several animal models 
in the field of cancer studies (Thomsen et al. 1997), diabetes (Cheng and Pang 2004), 
traumatic brain injury (Jafarian-Tehrani et al. 2005), but so far no reports on EAE have 
been found.   
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Chapter 2 
Aims of thesis 
 
 
The first aim of this thesis is to optimise electrophysiological tests in naïve animals to 
obtain reliable and reproducible recordings, in order to detect any neurological 
dysfunction in animals induced with EAE.  The second aim is to characterise the 
pathophysiology of animals with EAE at each five key stages along the disease course 
(‘preinduction’, ‘predisease’, ‘peak disease’, ‘remission’, ‘relapse’), using neurological, 
electrophysiological and histological assessments.  Finally, in order to explore whether 
modulation of inflammatory factors affect the disease course, a proinflammatory agent 
LPS and a selective iNOS inhibitor 1400W are used in these animals, and any changes 
will be detected by employing the set of assessments described above. 
Chapter 2.  Aims of thesis 
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Chapter 3.  Development of in vivo electrophysiological techniques 
3.1.  Introduction and aims 
 
Serial in vivo electrophysiological examinations can be useful when testing 
neurological functions in live animals, as it may reduce experimental errors that are 
more prone when results are compared between different animals.  In this chapter, I 
developed methods of electrophysiological tests in order to obtain serial recordings 
reliably.  These techniques have been successfully applied to the animals with EAE 
and the results are described in the following chapter.  
 
The aim of this chapter is firstly to introduce electrophysiological tests that were used 
to examine the animals.  The electrophysiological tests were employed to examine 
‘axonal conduction’, ‘motor neuronal excitability’, ‘synaptic transmission’, and 
‘synaptic activation of motor neurons’ within the central nervous system.  Secondly, 
each of these tests was optimised by looking at several factors which may contribute to 
the reliability of these recordings.  For example, the type of anaesthesia used, 
frequency of stimulation, and limb temperature were explored on motor neuronal 
excitability.  In addition, the effect of electrode positioning was investigated on 
recording synaptic transmission.  Finally, I aimed to develop a new method of 
examining the synaptic activation of motor neurons in the ventral horn.   
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3.2.  Methods  
 
3.2.1.  Animals 
 
Female Dark Agouti rats weighing 150-180 grams were purchased from Harlan 
Laboratories (UK), and were housed for one week prior to induction of EAE.  Rats 
were kept in groups of four to five per cage, and housed in the animal unit (Denny 
Brown Laboratories) at the Institute of Neurology, University College London.  
Animals were kept under controlled temperature (between 18~22°C) and maintained in 
a 12hr light/dark cycle in the unit.  All procedures were carried out in accordance with 
the requirements of the Animals (Scientific Procedures) Act 1986 and with ethical 
committee approval under a UK Home Office License. 
 
3.2.2.  Anaesthesia 
 
The rats were anaesthetised by inhaling 2 % isoflurane (Agar Scientific Ltd, UK) or by 
intraperitoneal injection of a combination of 90mg/kg of ketamine (Fort Dodge Animal 
Health Ltd, UK) and 10mg/kg of xylazine (Animal Care Ltd, UK).  The 
ketamine/xylazine combination was made as a stock solution and kept for less than a 
week at room temperature.   
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3.2.3.  In vivo electrophysiological assessments 
 
The rectal temperature of the rat was monitored during anaesthesia for 
electrophysiological assessment, and was maintained in the range of 36-37 °C by a 
heated blanket or by radiant heat when necessary.  The temperature of the foot was 
monitored by a thermistor attached to the plantar surface of the foot. 
Electrophysiological examination was performed using needle electrodes.  Compound 
responses were evoked using a signal generator (Neurolog module NL300, Digitimer, 
UK) and an isolated stimulator (DS2, Digitimer, UK).  Signals were recorded using a 
differential electrophysiological amplifier (Neurolog module NL104, Digitimer, UK), 
displayed on an oscilloscope (Sigma 60, Nicolet, UK), and saved as .wft files.  For 
analysis, the recordings were exported to Impression (Nicolet, UK) and Origin 6.1 
(Origin Coorporation, USA) for plotting as 3D ‘waterfall’ plots or superimposed 
recordings. 
 
3.2.3.1.  Examination of sensory compound action potentials (SCAP) 
 
Sensory compound action potential (SCAP) was evoked with the stimulating cathode 
resting on the vertebrae in the paravertebral muscle at the level of T10/T11 vertebral 
junction with the stimulating anode located over the shoulder blade, and a ground 
electrode was inserted into the skin of the animal between the stimulating and 
recording electrodes.  SCAP was recorded differentially with the active electrode at the 
base of the tail, and the indifferent through the tail tip.  The recordings were averaged 
(n=10). 
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3.2.3.2.  Examination of M responses, H reflexes and F waves 
 
The direct motor response M response, monosynaptically-evoked H reflexes, and 
antidromically-evoked F waves were examined by stimulating the sciatic nerve at the 
sciatic notch and recording at the muscles on the dorsum of the unilateral hind limb.  
Two stimulating electrodes (cathode and anode inserted adjacent to the nerve) and 
recording electrodes (active inserted through the skin of the foot dorsum, indifferent 
through the tip of the middle digit of the same foot) were used, and a ground electrode 
was inserted into the skin of the animal between the stimulating and recording 
electrodes.  At each stimulating site the stimulus intensity was gradually increased 
until the M response, and H reflex when present, could be recorded from the muscle.  
Following recording of the H reflex, the F wave could be observed by increasing the 
stimulus intensity up to supramaximal level. 
 
3.2.3.3.  Examination of cord dorsum potential (CDP) 
 
Cord dorsum potentials (CDP) were evoked with the stimulating cathode and anode 
inserted through the ventral and dorsal side of the base of tail respectively.  The 
responses were recorded by placing the active electrode on the vertebrae in the 
paravertebral muscle at the level of L4/L5, and the indifferent electrode into the skin of 
the animal parallel to the position of the active electrode. The ground electrode was 
inserted into the skin of the animal between the stimulating and recording electrodes.  
The recordings were averaged (n=10). 
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3.2.3.4.  Examination of synaptic activation of motor neurons (SAM) 
 
Synaptic activation of motor neurons (SAM) was evoked with the stimulating cathode 
resting on a vertebra in the paravertebral muscle at the level of T10/T11 vertebral 
junction, with the stimulating anode located over the shoulder blade, and a ground 
electrode inserted into the skin of the animal.  SAM was recorded with recording 
electrodes (active inserted through the skin of the foot dorsum, indifferent through the 
tip of the middle digit of the same foot), and a ground electrode was inserted into the 
skin of the animal between the stimulating and recording electrodes.   
 
3.2.4.  Histology 
 
3.2.4.1.  Perfusion and fixation 
 
The animals were anaesthetized under 2% isoflurane, and fixed by transcardial 
perfusion using rinse buffer (2000U/L heparin, 0.025% lidocaine, 0.002% NaNO2 and 
0.02M N-2-hydroxyethylpiperazine-NO-2-ethanesulphonic acid (HEPES; pH 7.4))  
and 4% glutaraldehyde (4% in 0.15M phosphate buffer).  The spinal cord of the rat 
was removed following laminectomy, and a transverse section (0.5mm) of the lumbar 
enlargement was processed into resin sections (see next section). 
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3.2.4.2.  Resin section processing 
 
The 0.5mm blocks of lumbar enlargement from different animals were kept in 4% 
glutaraldehyde, and then distributed in processing ‘honeycombs’ and washed with 
0.15M phosphate buffer overnight.  This ‘honeycomb’ with tissues was then placed in 
a container filled with 1.5% buffered osmium tetroxide solution, and left on an orbital 
shaker for 2 hours.  The tissues were washed in 0.14M phosphate buffer for 10 minutes, 
three times.  After the washes, the tissues were dehydrated by using a series of 
alcohols with ascending concentrations (15 minutes in 30% alcohol, 15 minutes in 
50% alcohol, 15 minutes in 90% alcohol, 3 x 20 minutes in 100% alcohol).  These 
dehydrated tissues were placed in 100% propylene oxide for 30 minutes twice, then in 
50% propylene oxide with 50% resin for 60 minutes, and in 25% propylene oxide with 
75% resin for another 60 minutes, and finally, in 100% resin overnight at 4  ̊C.   
Embedding of each tissue in the resin was carried out in a BEEM capsule to allow the 
cutting of transverse sections.  The whole capsule with its content was then placed in 
an oven with a temperature of 60 ̊C for 24-36 hours for polymerization.  For light 
microscopic examinations, transverse sections of the spinal cord with a thickness of 
1µm were obtained using a microtome (Leica Microsystems (UK) Ltd., Knowlhill, 
Buckinghamshire, Milton Keynes).  As the cut sections were initially floated on a 
water surface, they were dried on a hotplate at 60 ̊C after they were transferred onto 
the slides.  The sections were stained with 0.1% thionin acetate (50% ethanol, basic) 
and 1% aqueous basic acridine orange, and mounted in DPX (BDH, Poole, UK).  
These sections were viewed using a light microscope (Zeiss Axiophot, Germany) and 
digital photographs were taken by a PC- connected camera (D300, Nikon, Japan). 
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3.3.  Results 
 
3.3.1.  Introduction to in vivo electrophysiological examinations 
 
The main purpose of performing electrophysiological examinations is to determine the 
functional integrity of the nervous system.  To investigate the neurological functions 
within the central nervous system, I examined axonal conduction by recording the 
sensory compound action potential (SCAP), motor neuronal excitability by M response, 
the  H reflex, and F wave.  Also, synaptic transmission was examined by recording the 
cord dorsum potential (CDP), and synaptic activation of motor neurons (SAM) was 
monitored as well.  The representative recording and positioning of the needle 
electrodes (stimulation, recording and ground) are illustrated and described in the table 
below. 
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Table 3.1.  Battery of electrophysiological tests used in this study 
 
Representative trace Electrode positioning 
0.1mV
5ms
 
Figure 3.1(a) Sensory compound action 
potential 
 
 
 
 
 
Figure 3.1(b) Illustration of electrode 
positioning for recording SCAP 
Figure 3.1(a) shows the representative recording of sensory compound action potential 
(SCAP) which was averaged 10 times to minimise noise. The SCAP is a result of antidromic 
conduction in sensory axons evoked by supramaximal stimulation of the spinal cord at 
vertebral levels T10/T11, and recorded from the base of the tail, vs. an indifferent at the tip 
of the tail, as shown in Figure 3.1(b).  Ground electrode was placed between the stimulating 
and recording electrodes.   
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0.5mV
5ms
 Figure 3.2(a)  M response and H reflex 
 
   
 
Figure 3.2(b) Illustration of electrode 
positioning for recording  
Figure 3.2(a) shows a representative recording of an M response and H reflex.  The M 
response is an orthodromically conducted motor response recorded, in this case from the 
foot muscles, and evoked by stimulation of the sciatic nerve (as illustrated in Figure 3.2(b)).  
The H reflex results from the monosynaptic reflex from the activation of Ia sensory fibers 
and motor neurons.  The M response and H reflex in this trace were recorded at the 
threshold level of stimulation. 
5mV
5ms
 Figure 3.3(a) M response and F wave 
 
 
  
 
Figure 3.3(b) Illustration of electrode 
positioning for recording 
Figure 3.3(a) shows a representative recording of an M response and F wave, and Figure 
3.3(b) illustrates the positioning of the electrodes.  The M response is as previously 
described in Figure 3.2(a), whereas the F wave results from the ‘reflection’ of antidromic 
motor impulses from ventral horn motor neurons.  The M response and F wave in this trace 
were recorded at the supramaximal level of stimulation. 
M response 
F wave 
    M response 
    H reflex 
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0.05mV
5ms
 Figure 3.4(a) Cord dorsum potential (CDP) 
  
 
 
Figure 3.4(b) Illustration of electrode 
positioning for recording 
The cord dorsum potential is composed of two peaks which are the directly conducted 
action potential and the dorsal horn synaptic response (Figure 3.4(a)). The responses are 
evoked by stimulating the tail and recorded at the vertebral level of L4/L5 (Figure 3.4(b)). 
The directly conducted action potential appears with short latency, and the synaptically-
mediated responses from the dorsal horn appear in the records obtained from the location 
of the dorsal root entry zone (DREZ) of the tail roots.   
2.5mV
5ms
 Figure 3.5(a) Synaptic activation of motor 
neurons (SAM) 
 
 
 
 
Figure 3.5(b) Illustration of electrode 
positioning for recording 
The synaptic activation of motor neurons (Figure 3.5(a)) was obtained by giving a triple 
supramaximal stimulation separated by 1 millisecond at the vertebral level of T10/T11, and 
recorded from the foot muscles (Figure 3.5(b)).  This recording is a sum of both ‘H reflex- 
like response’, and the corticospinal tract response (validation method is described in 
section 3.3.2.4.)   
 
Dorsal horn 
synaptic 
response 
Direct action potential 
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3.3.2.  Optimisation of electrophysiological examinations 
 
Electrophysiological recordings are affected by several factors, including the type of 
anaesthetic agent used, the temperature of recording site of the animal, the frequency of 
stimulation, and positioning of the electrodes.  As the aim was to obtain serial recordings 
reliably, optimisation of these parameters is required. 
Here, the effects of different anaesthetic agent by using isoflurane and ketamine/xylazine, 
frequency of stimulation, and temperature of the foot were explored on recordings of M 
responses, F waves and H reflexes.  Also, positioning of recording electrodes was shown to 
affect the amplitude of the cord dorsum potential (CDP).  Furthermore, recordings of 
synaptic activation of motor neurons (SAM) were developed and validated by cutting the 
dorsal roots to eliminate ‘H reflex- like response’. 
 
3.3.2.1.  The effect of different anaesthesia and frequency on M response, F 
wave and H reflex 
 
F waves and H reflexes are recognised measures of motor neuronal function, but they are 
also well known for being inherently variable.  Therefore, in order to obtain reliable and 
reproducible F waves and H reflexes, I tested two types of anaesthesia, namely 
isoflurane and ketamine/xylazine, and also applied different frequencies to obtain the 
best recordings.  Rats were anaesthetised either by the inhalation of 2% isoflurane, or 
by the intraperitoneal injection of a combination of 90mg/kg of ketamine and 10mg/kg 
of xylazine, and prepared for electrophysiological examination.  H reflexes and F 
waves were recorded under each anaesthetic agent using different frequencies of 
stimulation (0.1Hz, 1Hz, 2Hz and 5Hz).  Both the H reflex and the F wave showed 
larger response amplitudes under ketamine/xylazine than under isoflurane, whilst the 
M responses were not influenced (Figure 3.6).  Furthermore, when the stimulations 
were given at different frequencies, the H reflexes and F waves were best elicited at 
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the lowest frequency of 0.1Hz, and their amplitude decreased as the frequency 
increased.  Again, the M responses were not affected by the change of stimulation 
frequencies.  From these data, ketamine/xylazine was selected as the anaesthetic agent 
for subsequent electrophysiological examinations, and a frequency of 0.1 Hz was 
chosen when recording the H reflexes and F waves. 
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Figure 3.6.  M response, H reflex and F wave recorded under isoflurane and 
ketamine/xylazine anaesthesia at different frequencies 
Figure shows that the M response, H reflex and F wave were elicited under isoflurane and 
ketamine/xylazine anaesthesia. The H reflexes and F waves were recorded at the threshold 
level and the supramaximal level of stimulation respectively. Both H reflexes and F waves 
showed the largest amplitude under ketamine/xylazine, and at the low frequency of 0.1Hz (b, 
d).  Under isoflurane anaesthesia, the H reflex could not be recorded at all (a), and F waves 
showed a smaller response amplitude (c).  However, the M response was not affected by the 
type of anaesthesia, nor the change in frequency. 
 
 Isoflurane Ketamine/Xylazine 
M response 
and         
 H reflex 
 
 
M response 
and          
 F wave 
 
 
A 
C D 
B 
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3.3.2.2.  The effect of temperature on F waves and H reflexes  
 
Although the rectal temperature of the animals was monitored and maintained to be in 
the range of 36-37  ̊C under anaesthesia, during winter times the animals presented 
cooler extremities due to cooler air in our poorly heated laboratory.  In these cases, a 
prolonged latency and duration  of the recorded M responses, H reflexes and F waves 
were noticeable, so a radiant heat lamp was used to keep the limbs warm.  In order to 
assess the need to maintain the limb temperature within a certain range, I have 
investigated the effects of temperature on M responses, H reflexes and F waves.  An 
ice bag was used to cool the hindlimb temperature, and a thermistor was attached to 
the plantar surface of the foot for monitoring.  It is realised that the practice of 
recording the temperature in the foot will have exaggerated the apparent changes in 
temperature of the leg, but the foot provides a convenient and indicative temperature.  
The temperature of the plantar surface was between 31–32  ̊C in naïve rats.  The 
recordings of the M response, H reflex and F wave were taken at this temperature and 
at every 1 ̊C decrease of the temperature.  Figure 3.7 and 3.8 show the recordings 
obtained.  When the latency (time till onset of the ensuing action potential) of each 
recording was measured and plotted against the temperature, a positive correlation was 
shown (Figure 3.9 and 3.10).  The latency of the M response evoked by supramaximal 
stimulus of the sciatic nerve increased approximately 0.2ms per 1 ̊C decrease of 
temperature.  Also the latency of the H reflex and F wave increased approximately 
0.17ms and 0.4ms per 1 ̊C decrease of temperature respectively.  These data show that 
maintaining consistenty of the hindlimb temperature when recording the M response, 
H reflex and F wave is crucial when accurately analysing consecutive recordings of 
EAE animals over days.  
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Figure 3.7. Superimposed recordings of M responses and H reflexes taken at different 
temperatures 
M responses and H reflexes were recorded at every 1 ̊C decrease of temperature of the foot 
from normal status (recordings are superimposed but in practice appear to start from left to 
right in different colours).  Both M response and H reflex show increased latency, duration, 
and amplitude as the temperature cools.  
 
 
 
Figure 3.8. Superimposed recordings of M responses and F waves taken at different 
temperatures 
M responses and F waves were recorded at every 1 ̊C decrease of temperature of the foot from 
normal status (Recordings start from left to right in different colours).  Both M response and F 
wave show increased latency, duration, and amplitude as the temperature cools.  
M response 
H reflex 
F wave 
M response 
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Figure 3.9. Latency (ms) of M response and H reflex, plotted against temperature decrement 
The latency of M response and H reflex from each recording in Figure 3.7 was measured and 
plotted against temperature decrement by 1 ̊C. The latency of the M response increased 
approximately 0.2ms per 1 ̊C decrease of temperature.  The latency of the H reflex was 
increased by approximiately 0.17ms per 1 ̊C decrease of temperature. 
 
 
Figure 3.10. Latency (ms) of M response and F wave, plotted against temperature decrement 
The latency of M response and F wave from each recording in Figure 3.8 was measured and 
plotted against temperature decrement by 1 ̊C. The latency of the M response increased 
approximately 0.2ms per 1 ̊C decrease of temperature.  The latency of the F wave was 
increased by approximiately 0.4ms per 1 ̊C decrease of temperature. 
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3.3.2.3.  Developing recording methods for the cord dorsum potential (CDP) 
to examine synaptic transmission 
 
The cord dorsum potential (CDP) can be recorded by stimulating the peripheral tail 
nerves and recording rostro-caudally along the dorsal surface of the spinal cord (Figure 
3.4(b) illustrates electrode positions).  Figure 3.11 is a ‘waterfall’ plot showing a series 
of compound action potentials recorded at different locations along the spinal cord in 
response to supramaximal stimulation applied at the base of the tail.  The most caudal 
recording is shown at the front (lowest record shown).  The responses are recorded 
from the level of the L6/S1 vertebral junction, up to the level of T12/T13.  The directly 
conducted action potential appears with short latency, and the synaptically-mediated 
responses from the dorsal horn appear in the records obtained from the location of the 
dorsal root entry zone (DREZ) of the tail roots.  This response becomes larger than the 
primary volley due to an amplification process occuring in the cord, and it reaches a 
maximum over the lumbar enlargement, i.e. the location of the DREZ.  The recording 
shown in red was made at vertebral level L4/L5, and it was chosen for analysis as it 
showed a clear distinction between the two responses. 
 
 
 
59 
 
                                                          
 
Figure 3.11.  ‘Waterfall’ plot of the cord dorsum potential (CDP) recorded from L6/S1 to 
T12/T13 
The cord dorsum potential (CDP) was recorded by stimulating the peripheral tail nerves and 
recording at the dorsal surface of the spinal cord.  The ‘waterfall’ plot shows the most caudal 
recording at the front (lowest recording) at the vertebral junction of L6/S1 and up to the level 
of T12/T13.  The primary peak is the direct action potential that travelled along the fibers of 
the spinal roots to the dorsal column.  The second peak is a result of post-synpatic activation 
primarily from the dorsal horn cells, and it shows the largest volley at the L4/L5 vertebral 
level (shown in red), with a clear distinction from the direct action potential peak.  
 
 
 
 
 
 
 
L6/S1 
T12/T13 
L4/L5 
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As shown in Figure 3.11, the amplitude of the synaptic potential was the largest, and 
also clearly distinct from the direct action potential (short latency peak), at the 
vertebral level of L4/L5, and accordingly this junction was chosen as the recording site.  
Next, I aimed to map the traces accurately by recording at every 1mm from L4 up to 
the L5 vertebra within the junction, so that one can accurately position the active 
recording electrode within the junction for recording the CDP.  Figure 3.12 shows that 
there was an increase of the amplitude of the synaptic transmission when the recording 
electrode was placed 2mm rostral to the L5 vertebrae.  However, the amplitude of the 
direct action potential was stable regardless of the electrode position. 
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Figure 3.12.  Diagram of L4/L5 vertebral junction and ‘superimposed’ plot of spinal cord 
dorsum potentials (CDP)  
The spinal cord dorsum potential (CDP) was recorded within the L4/L5 vertebral junction by 
stimulating the base of the tail.  The diagram (a) shows the L4 and L5 vertebrae and the 5 
points within the junction where the cathodic needle electrode were positioned for recording.  
The ‘superimposed’ plot (b) shows CDP recordings made at these 5 points.  The potential 
resulting from synaptic transmission (the second peak) increased when the electrode was 
positioned 2mm rostral to the L5 vertebra, and remained at a similar amplitude up to the L4 
vertebra.  
 
 
 
 
 
 
 
 
A B 
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3.3.2.4.  Developing recording methods of synaptic activation of motor 
neurons (SAM) 
 
The H reflex has been previously described as a means of examining synaptic transmission 
between the Іa sensory axons and α motor neurons.  Here, another method of examining the 
synaptic activation of motor neurons has been developed.  Whilst the H reflex recording 
involves threshold stimulation of the sciatic nerve, this new method uses supramaximal or 
near supramaximal stimulation to activate the dorsal horn axons at the T10/T11 vertebral 
junction (as illustrated in Figure 3.5(b)).  When this region is stimulated, both the 
corticospinal tract axons and the dorsal column sensory axons are activated which both 
synapse on the motor neurons that innervate the foot muscles.  Hence this recording was 
named ‘synaptic activation of motor neurons (SAM)’ (illustrated in Figure 3.14).  The 
sensory axons of the dorsal column elicit an ‘H reflex-like response’, as they synapse on the 
motor neurons likewise to the Іa sensory axons as a result of sciatic nerve stimulation.   
 
In order to explore the contribution of this ‘H reflex-like response’ to SAM, we severed the 
left L4, L5 and L6 dorsal roots (surgery performed by Professor Kenneth Smith) which 
convey the sensory signal through sensory Іa  fibres under general anaesthesia (illustrated in 
Figure 3.13).  After the surgery, the animal did not show a pinch withdrawal reflex in the left 
leg, which correlated with a sensory pathway dysfunction due to the dorsal root cut.  SAM, 
H reflex, and F wave recordings were made at both the left and right side of the animal, 
before and after severing the roots, and at four days after the surgery when the sensory axons 
would have been degenerated.  The EMG recordings of these tests are shown in Figure 3.15.  
None of the recordings taken from the right side were affected throughout the examinations, 
whilst the recordings from the left side were profoundly affected.  The left H reflex 
amplitude had decreased after the surgery, which indicates the dorsal roots were cut 
successfully, as the dorsal roots convey the afferent sensory signals (Figure 3.15 (c)).  
Interestingly, the decrease in the amplitude of left SAM at day four (Figure 3.15 (a)) after the 
surgery suggests that SAM is likely to be composed of both the ‘H reflex-like response’, and 
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corticospinal tract response.  The ‘H reflex-like response’ may have diminished as a result of 
axonal degeneration in the dorsal column occurring from the severance of the dorsal roots.  
The F wave had also decreased at day four post surgery, which may be due to inflammation 
around the motor neurons occurring due to the degeneration of the Іa afferent terminals.  
However, we have not found supporting evidence from examinations of resin sections. 
 
After the electrophysiological recordings on day four after surgery, the animal was perfused 
and fixed for histological examinations.  Figure 3.16 (a) shows the spinal cord with the left 
dorsal roots cut, and Figure 3.16 (b) is a magnified picture of the dorsal column.  Wallerian 
degeneration was observed within the left side of the dorsal column, which may explain why 
the amplitude of SAM had been reduced.  Unilateral degeneration was obvious as shown in 
Figure 3.16 (c) and (d), where almost every axon in the left dorsal root was degenerated.   
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Figure 3.13.  Diagram showing dorsal root cuts  
The L4, L5 and L6 dorsal roots were severed in order to examine the contribution of ‘H reflex-like 
responses’ to the recordings of synaptic activation of motor neurons (SAM).  
 
 
 
Figure 3.14.  Proposed pathway of stimulating and recording ‘synaptic activation of motor 
neurons (SAM)’ 
This diagram illustrates the stimulation and recording site for recording SAM.  Stimulation and 
recording electrodes were placed at the vertebral junction of T10/T11 and foot dorsum respectively.  
When the vertebral junction of T10/T11 is stimulated, both the sensory axons and corticospinal tract 
are activated.  Activation of both of these pathways triggers the motor neurons in the ventral horn by 
synaptic transmission, therefore activating the foot muscles. 
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(a) Left side ‘waterfall’ SAM                               (b) Right side ‘waterfall’ SAM 
 
(c) Left side ‘waterfall’ H reflex                           (d) Right side ‘waterfall’ H reflex 
 
(e) Left side ‘waterfall’ F wave                               (f) Right side ‘waterfall’ F wave 
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Figure 3.15.  EMG recordings showing synaptic activation of motor neurons (SAM), H reflex, and  
F waves 
Synaptic activation of motor neurons (SAM), H reflex and F wave recordings were examined in an 
animal before and after the left L4, L5 and L6 dorsal roots were cut, and also at four days post 
surgery.  The recordings performed at the right side were similar on each recording occasions ((b), 
(d), (f)), while the left side recordings were affected.  A waterfall plot of H reflex (c) shows that the H 
reflex was completely absent after the dorsal root cut.  However, (a) shows that the SAM had 
decreased when examined four days after surgery.  This indicates that the SAM may be composed of 
both the ‘H reflex-like response’ and the corticospinal tract response.  Here, the reduction is likely to 
be due to axonal degeneration occurring in the left side of the dorsal column (shown in Figure 3.16).  
(e) shows a waterfall plot of F waves.  At day four post-surgery, the F wave was decreased, which 
could be due to inflammation around the motor neurons resulting from the degeneration of the 
terminals of the Іa afferent axons. 
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Figure 3.16. Histological examination of the spinal cord and dorsal roots 
This figure shows the unilateral axonal degeneration (left side of the cord) four days post-
surgery. The animal was perfused with glutaraldehyde after electrophysiological examinations.  
(a) shows the transverse section of the whole spinal cord, and the highlighted red boxes 
indicate the magnified areas shown as (b), (c),  and (d).  (b) shows the dorsal part of the 
dorsal column, which shows a clear distinction between the degenerated axons on the left, and 
the intact axons on the right side.  The axons in the left side of the dorsal column show 
Wallerian degeneration.  (c) shows at high magnification of the left damaged root, which also 
shows that the axons are degenerated, whilst the right dorsal root is intact (d). 
(Black scale bar=1000µm , white scale bar=250µm) 
 
A 
C 
B 
D 
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3.4.  Conclusion 
 
This chapter shows that optimising the examining conditions is essential in obtaining 
reliable in vivo electrophysiological recordings.  Anaesthetic agents should be 
carefully selected depending on the type of recordings made, and stimulation 
frequency and temperature of the animal must be taken into account when interpreting 
the recordings.  Here, I showed that motor neuronal excitability (H reflexes and F 
waves) were better evoked under ketamine/xylazine, than under isoflurane, and at the 
lowest frequency of stimulation (0.1 Hz).  Also, the negative correlation between 
latency and temperature finding can be informative when examining animals with 
different limb temperatures. These data can be particulary useful in understanding the 
increased latency of animals with EAE described in the next chapter, since these 
animals showed hypothermia.  
    
All the in vivo electrophysiological methods described so far have been applied in the 
animals with EAE described in the following chapter, in order to understand the 
mechanisms responsible for the transient peak, recovery and relapse present within the 
disease course. 
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Chapter 4.  Neurological, histological and electrophysiological assessment of 
DA rats induced with rMOG-EAE 
4.1. Introduction and aims 
 
Relapsing- remitting multiple sclerosis (RR-MS) is the most common form of multiple 
sclerosis affecting around 80% of the patients.  However, the mechanisms underlying 
the different phases are still not completely understood.  
 
In this chapter, I aimed to explore the possible mechanisms by using a rat model of 
EAE that closely resembles the symptoms and pathology of MS.  Dark Agouti (DA) 
rats were induced with EAE using recombinant myelin oligodendrocyte glycoprotein 
(rMOG), and five key stages along their disease course were characterised using 
neurological examinations.  These stages are ‘preinduction (PI)’, ‘predisease (PreD)’, 
‘peak disease (PD)’, ‘remission (REM)’ and ‘relapse (REL)’.  At these five stages, 
electrophysiological tests that were described in the previous chapter were employed 
to examine any dysfunction of axonal conduction, motor neuronal excitability, 
synaptic transmission and synaptic activation of motor neurons within the central 
nervous system.  Furthermore, histological analysis of these animals at equal stages 
was performed in order to examine the degree of inflammation, demyelination and 
axonal degeneration occurring in the spinal cord.  The pathology of the dorsal column 
was also investigated in order to explore the correlation with axonal conduction 
measured from the dorsal column axons.   
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4.2.  Methods 
 
4.2.1.  Animals and anaesthesia  
 
The methods have been previously described in Chapter 3, Methods 3.2.1 and 3.2.2. 
Animals that reached a neurological score of more than five were provided with 
mashed food in water on the floor of the cage.  
 
4.2.2.  Rectal temperature monitoring in non-anaesthetised animals 
 
Rectal temperature was measured by inserting a rectal temperature probe into the 
rectum of a rat without anaesthesia.  The temperature was recorded when the reading 
was stable for at least five seconds. 
 
4.2.3.  Induction of experimental autoimmune encephalomyelitis (EAE) with 
recombinant myelin oligodendrocyte glycoprotein (rMOG) 
 
Recombinant myelin oligodendrocyte glycoprotein (rMOG) was kindly provided by 
Professor Chris Linington (University of Glasgow).  A total volume of 200µl emulsion 
was made by adding 0.1mg of rMOG and incomplete Freunds adjuvant (IFA) using 
glass Hamilton syringes.  For induction of EAE, the animals were shaved at the dorsal 
base of the tail under 2% isoflurane, and the emulsion was injected subcutaneously.   
For control animals, 200µl of IFA was injected.   
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4.2.4.  Neurological assessments 
 
Rats with EAE were weighed and scored for the magnitude of any neurological 
deficits, and this was performed at a designated time each day to minimise any 
circadian variability.  Neurological assessment was performed by giving a daily 
‘neurological score’ to every animal induced with EAE using a ten point scale system 
(Table 4.1.).   
  
Table 4.1. Ten point scale system for neurological scoring 
Score Signs 
1 Reduction of muscle tone of tail tip 
2 Reduction of muscle tone of the whole tail 
3 Tail paralysis 
4 Inability to spread toes 
5 Unsteady gait 
6 Hind limb paresis (one side) 
7 Hind limb paresis (other side) 
8 Hind limb paralysis (one side) 
9 Hind limb paralysis (other side) 
10 Moribund/dead 
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For the study described in this chapter, five key stages along the disease course of 
EAE were selected for electrophysiological and histological analyses.  These stages 
were ‘preinduction (PI)’, ‘predisease (PreD)’, ‘peak disease (PD)’, ‘remission (REM)’ 
and ‘relapse (REL)’.  Selection criteria for these stages are described in Table 4.2 
below. 
 
Table 4.2.  Selection criteria of five key stages along the disease course of EAE 
Stages Criteria 
Preinduction 
(PI) 
Before induction of EAE (naїve). 
Predisease 
(PreD) 
5 days after the induction of EAE, prior to the 
onset of neurological deficit. 
Peak disease 
(PD) 
First peak of the disease, where neurological score 
is between seven and nine. 
Remission 
(REM) 
Recovery from the first peak of disease, the rats 
remain as a score of three to five for at least two 
days. 
Relapse  
(REL) 
Second peak of disease, after experiencing both 
peak disease (PD) and relapse (REL).  The 
neurological score is between seven and nine. 
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4.2.5.  Behavioural assessments by inclined plane measurements 
 
The inclined plane is a tool designed for quantitative measurement of limb motor 
function.  A ball screw is used to adjust the angle of the plane (Chang et al. 2008).  
The inclined plane used in this study was designed by Dr Andrew Davies from our 
laboratory.  Behavioural assessments were performed by measuring the maximum 
angle of an inclined plane, at which the animal could stay on the plane without sliding 
down the plane for 10 seconds.  Sandpaper was used to cover the plane, and was 
changed regularly to reproduce similar friction for each experiment. 
 
4.2.6.  Histological assessments 
 
4.2.6.1.  Perfusion and fixation 
 
The animals were anaesthetised under 2% isoflurane, and fixed by transcardial 
perfusion using rinse buffer and 4% paraformaldehyde (4% in 0.15M phosphate 
buffer).  The spinal cord of the rat was removed following laminectomy, and a 0.5mm 
transverse section was cut at L1/L2 vertebral junction for processing into resin blocks 
which were re-fixed in 4% glutaraldehyde (4% in 0.15M phosphate buffer).  The 
remaining spinal cord was kept in 4% paraformaldehyde for processing into frozen 
sections for immunohistochemical analysis.  
 
4.2.6.2.  Resin section processing and quantification of pathology 
 
75 
 
The details of the resin section procedures have been described previously in Chapter 3, 
Methods section 3.2.4.2.   
Quantification of pathology in resin sections of the spinal cord was achieved using 
Image J software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009).  The images of the 
spinal cord that were viewed and taken using the light microscope and camera were 
converted into a grayscale 8-bit file to measure the pathological areas.   
In this study, pathological areas of both ‘white matter’ and ‘dorsal column’ were 
estimated by drawing around the area of interest.  To obtain the ‘percentage area of 
pathology in the white matter’, the ‘total area of axonal degeneration and 
demyelination’ was divided by the ‘area of white matter’ and the answer x100.  
Likewise, the ‘percentage area of pathology in the dorsal column’ was calculated by 
dividing the ‘total area of axonal degeneration and demyelination in the dorsal column’ 
by the ‘area of dorsal column’ x100.  In addition, within the dorsal columns, the ‘area 
of axonal degeneration’ and the ‘area of demyelination’ were measured separately, and 
these values were divided by the ‘area of dorsal column’ to assess the ratio of the two 
pathological features.   
 
4.2.6.3.  Frozen section processing for immunohistochemistry 
 
Spinal cord which was fixed and kept in 4% paraformaldehyde overnight was moved 
into 30% sucrose for 3 days.  A one centimetre block centred at the L1/L2 vertebral 
junction was embedded in a mould made with foil filled up with OCT (Bright, 
Huntingdon, UK).  These blocks were then frozen in liquid nitrogen and kept at -20  ̊C 
before cryosectioning.  Spinal cords were sectioned in 12 µm sections using a freezing 
crytostat (CM 1950, Leica, Milton Keynes, UK).  The tissue sections were carefully 
collected on a glass slide and kept at -20  ̊C until immunohistochemical labelling. 
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4.2.6.4.  Immunohistochemistry and quantification 
 
Sections for immunohistochemical analysis were air-dried on slides for at least an hour 
and then washed with phosphate buffered saline (PBS) for 5 minutes.  After the wash, 
the slides were pre-treated with hydrogen peroxide (H2O2) to eliminate endogenous 
peroxidase activity, and blocked with appropriate non-immune serum.  The detailed 
protocol for pre-treatment is described in Table 4.3.  After blocking, tissue sections 
were washed with PBST (0.05% Tween 20 dissolved in PBS) and incubated in 
appropriate primary antibodies overnight at either room temperature or 4 °C.  Negative 
control slides were incubated with PBS without antibodies for the same length of time.  
Table 4.4. describes appropriate concentrations, time and temperature of treatment for 
each antibody used in this study.   
After treatment with the primary antibody, the slides were washed with PBS 3x5 
minutes to remove excess antibodies, and then incubated with appropriate biotinylated 
secondary antibody (Goat anti rabbit (BA1000) or horse anti mouse (BA2001), Vector 
labs, Peterborough, UK) for 45 minutes at room temperature.  Secondary antibodies 
were selected depending on the species in which the primary antibody was produced.   
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Table 4.3. Pre-treatment information for different antibodies 
Antibody H2O2 treatment Blocker treatment 
ED1 30% H2O2 in methanol for 20 
minutes at room temperature 
10% normal horse serum for 1 hour at room 
temperature 
iNOS 30% H2O2 in PBST (0.05% Tween 
20 dissolved in PBS) for 20 minutes 
at room temperature, followed by 
70% cold methanol for 20 minutes 
at room temperature 
10% normal horse serum for 1 hour at room 
temperature 
 
 
Table 4.4. Properties of primary antibodies used in this study 
Antibody Source Dilution Time/temperature 
of treatment 
Company Cat no. Lot/batch 
ED1 Mouse 1:200 Overnight at room 
temperature 
Serotec MCA341R 060509 
 
iNOS Rabbit 1:200 Overnight at room 
temperature 
BD 
Biosciences 
610333 54151 
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To remove excess secondary antibodies, the slides were washed with PBS 3x5 minutes. 
Following the washes, the sections were incubated in an Avidin Biotin Complex (ABC 
Elite kit, Vector labs, Peterborough, UK) for 45 minutes at room temperature.  After 
another three washes with PBS, the chromogen diaminobenzidine (DAB) 
tetrahydrochloride (Vector labs, Peterborough, UK) was used to visualize the antibody 
binding.  Incubation time was optimized depending on the specific protein under study 
and sections were checked under the microscope regularly until the optimum colour 
with the least background was achieved.  The sections were then dehydrated by 
passing them through increasing concentrations of ethanol (70% for 5 minutes, 90% 
for 5 minutes, 95 % for 5 minutes, 100% for 2 minutes x 2, xylene for 5 minutes x 2). 
A coverslip was then applied with DPX mounting medium (Fluka Chemie, Buchs, 
Switzerland) and slides were left to air-dry overnight.   
The quantification of immunohistochemical labeling was achieved by using the Image 
J software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,  
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009).  Images of the spinal cord that 
were viewed and taken using the light microscope and camera were converted into a 
grayscale 8-bit file.  Whilst keeping the ‘contrast/brightness’ consistent in all images, 
the immunohistochemical labelling was converted into dark particles.  The darkness 
and circularity of these particles were thresholded and defined to detect 
immunohistochemical labelling.  The total area of the dark particles was measured and 
divided by the ‘area of spinal cord’ to obtain the ‘percentage area of labelling’. 
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4.2.7.  Electrophysiological assessment 
 
Animals induced with EAE were examined at different stages of the disease using the 
electrophysiological tests introduced in Chapter 3.  Detailed methods of these 
electrophysiological examinations have been described previously (Chapter 3, 
Methods section 3.2.3). 
 
4.2.8.  Statistics 
 
Data were expressed with means and standard deviations, and plotted using   
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, USA). 
One-way ANOVA with Newman-Keuls post test was performed to compare the means 
in three or more groups, Spearman’s rank correlation test was used for correlation 
analysis.  ‘Statistical significance’ was determined by the p value obtained from these 
tests.  (p<0.05 (*), p<0.01 (**), p<0.001 (***)) 
 
4.2.9.  Plan of experiment 
 
Figure 4.1 describes the disease course of EAE and the types of examinations 
performed along the disease course.  The horizontal axis and vertical axis indicate the 
‘time course of EAE’ and ‘severity of the disease’ respectively.  The disease course 
shown in a black line is characterised by five key stages, which is composed of two 
peaks, namely the ‘peak disease (PD)’ and ‘relapse (REL)’ with a remission phase 
‘remission (REM)’ in between.  ‘preinduction (PI)’ indicates a time period before 
inducing EAE and ‘predisease (PreD)’ indicates a time taken at 5 days after induction 
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when there are no neurological signs observed in these animals.  Neurological 
examinations including neurological scoring, weight measurements, inclined plane 
tests, and rectal temperature measurements were performed every day after the 
induction, until the end of the study.  However, electrophysiological and histological 
examinations were performed selectively at the five key stages.  
 
 
 
Figure 4.1.  Diagram of experimental plans for this study 
Neurological examination was performed daily after induction of the disease, whereas 
electrophysiological and histological assessments were made at five key stages along the 
disease course.  These stages are ‘preinduction (PI)’, ‘predisease (PreD)’, ‘peak disease 
(PD)’, ‘remission (REM)’, and ‘relapse (REL)’.  Animals were scored using a ten point scale 
and were appointed to the key stages using the selection criteria described previously (Table  
4.2).   
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4.3.  Results 
 
4.3.1.  Neurological assessment 
 
4.3.1.1. Neurological scoring and weight measurements 
 
Initially 15 rats were induced with EAE for neurological scoring and ten of these were 
included in the analysis illustrated in Figure 4.2.  One rat did not present any 
neurological signs, 2 died at their first peak of disease, and the other 2 were culled 
according to the Animals Act 1986 when they were found as moribund.  After 
induction of EAE, ten rats gradually gained neurological signs such as tail weakness 
and paralysis, and reached the peak of disease showing hindlimb paralysis, around day 
18-20 post induction.  The animals recovered from some of these signs around day 22-
24 post induction, and relapse occurred showing severe characteristics of the disease, 
around day 28-30 post induction.  Figure 4.2 (a) shows the daily averaged neurological 
score of ten animals, and (b) shows the average of neurological scores collected from 
these animals at the five stages of EAE (‘preinduction (PI)’, ‘predisease (PreD)’, ‘peak 
disease (PD)’, ‘remission (REM)’, ‘relapse (REL)’), selected according to the selection 
criteria described in Table 4.2.  At these stages the mean neurological scores of 
animals were 0, 0, 8, 3.25, 8.08 respectively.  The mean neurological scores at the 
‘peak disease (PD)’ and ‘relapse (REL)’ were significantly higher than ‘preinduction 
(PI)’ (P < 0.001).  Also, the mean difference was significant between ‘peak disease 
(PD)’ and ‘remission (REM)’ (P < 0.001), and between ‘remission (REM)’ and 
‘relapse (REL)’ (P < 0.001).   
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Figure 4.2.  ‘Neurological score’ plotted against time, and at the five key stages of EAE 
Neurological scores were assessed daily in animals induced with EAE after the induction of 
disease.  (a) The first peak of the disease occurred around day 18-20, and was followed by 
remission around day 22-24.  The animals slowly gained neurological signs after the 
remission, and reached their relapse (around day 28-30) (N=10 in each group, red; EAE, 
green; IFA control, black; naїve control).  (b) The mean neurological scores were 0, 0, 8.5, 
3.3, 8.6 at ‘preinduction (PI)’, ‘predisease (PreD)’, ‘peak disease (PD)’, ‘remission (REM)’, 
‘relapse (REL)’.  The mean neurological score at the ‘peak disease (PD)’ and ‘relapse (REL)’ 
were significantly higher than ‘preinduction (PI)’ (P < 0.001).  Also, the difference was 
significant between ‘peak disease (PD)’ and ‘remission (REM)’ (P < 0.001), and between 
‘remission (REM)’ and ‘relapse (REL)’ (P < 0.001) (N=10 in each group).  (P value was 
obtained by One way ANOVA, Newman-Keuls post test). 
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The weight of these animals was also monitored daily, and it was found that animals 
with a more severe disease course lost more weight than the ones with milder courses.  
Hence, the weights of the severe animals and mild animals were compared.  Animals 
that were selected for severe and mild disease course showed a neurological score of 
more than six (at least paresis on one side was observed), and not more than five (no 
paresis), respectively, at both their ‘peak disease (PD)’ and ‘relapse (REL)’.  Figure 
4.3 shows that animals with severe neurological scores showed significant weight loss 
at the ‘peak disease (PD)’ (p<0.01 to ‘preinduction (PI)’) and ‘relapse (REL)’ (p<0.01 
to ‘preinduction (PI)’).  However, mild animals did not show any decrease of weight 
along the entire disease course.   
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Figure 4.3.  Comparison of the weight between animals with a mild and severe disease 
course at the five key stages of disease 
Animals with EAE were weighed every day, and the mean weights were plotted at five time 
points along the time course of EAE.  The mild animals (black boxes, N=6) which did not 
reach a score of more than five did not show loss of weight throughout the disease course.  
However, the severe animals (red triangles, N=8) lost weight significantly at the ‘peak disease 
(PD)’ compared to ‘preinduction (PI)’ (P < 0.01), followed by an increase at ‘remission 
(REM)’.  At ‘relapse (REL)’, these animals lost significant amount of weight compared with 
‘preinduction (PI)’ (P < 0.01).  (P value was obtained by One way ANOVA, Newman-Keuls 
post test). 
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4.3.1.2. Behavioural tests using inclined plane 
 
An inclined plane test was used as a quantitative measure of motor function.  Firstly, in 
order to test reproducibility of the measurements, five naїve rats were examined every 
half an hour for two hours, and daily up to five days.  The angle of the inclined plane 
that these animals could stay on was between 49°-52° (Figure 4.4).  Therefore, this 
range of angles was used to determine the normal motor function of the limb in the 
following experiments using rats with EAE. 
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Figure 4.4.  Reproducibility of inclined plane measurements in naїve animals 
The inclined plane measurements were performed in five naїve animals over five days.  It 
shows that the range of angles that the rats could stay on without sliding down the plane for 
10 seconds were between 49° and 52°.   
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Following the reproducibility test in naïve animals, the inclined plane measurement 
was performed in EAE animals and controls (IFA and naїve) at the five key stages of 
disease.  As expected, in animals with EAE, motor function of the limbs was 
significantly decreased at the ‘peak disease (PD)’, and ‘relapse (REL)’ compared with 
‘preinduction (PI)’ (p<0.001).  However at ‘remission (REM)’, the angle significantly 
increased in association with recovery from the hindlimb paralysis at the ‘peak disease 
(PD)’ (P<0.001).   
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Figure 4.5.  Inclined plane measurements along the course of EAE 
Inclined plane measurement was performed in animals with EAE (N=17), controls (IFA (N=5) 
and naїves (N=5)).  Control animals showed normal motor function of the limb and the 
measurements were within the normal range (49-52°).  However, animals with EAE showed a 
significant decrease at the ‘peak disease (PD)’ compared with both ‘preinduction (PI)’(P < 
0.001) and ‘predisease (PreD)’(P < 0.001).  The ability to stay on the plane was significantly 
increased at ‘remission (REM)’ in contrast to ‘peak disease (PD)’ (P<0.001), but decreased 
again at ‘relapse (REL)’ (P<0.001).  (P value was obtained by One way ANOVA, Newman-
Keuls post test).  
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To explore whether the inclined plane measurements correlate with the neurological 
scores, a dot plot was used to compare the two values (Figure 4.6).  There was a 
significant negative correlation between the ‘inclined plane angle’ and ‘neurological 
score’ (the Spearman r value was -0.86, and P<0.0001).  These results show that the 
inclined plane test can be used in conjunction with neurological scoring in order to 
assess neurological deficits in animals with EAE. 
 
 
  
Figure 4.6.  Correlation between the inclined plane measurements and neurological scores 
in animals with EAE 
Inclined plane measurement was performed in EAE animals with various neurological scores 
(N=17).  The graph shows that there was a significant negative correlation between the 
‘inclined plane angles’ and ‘neurological scores’ in these animals.  The Spearman r value was 
 -0.86, and P<0.0001 (Spearman’s rank correlation test). 
  
 
R= -0.86 
P<0.0001 
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4.3.1.3. Rectal temperature measurements 
 
It is good practice to monitor the rectal temperature of the animals during 
electrophysiological recordings or surgery under anaesthesia.  However, while 
handling non-anaesthetised EAE animals, it was noticed that they had lower 
temperature at the ‘peak disease (PD)’ than naїves.  Based on this observation, I 
measured the core temperature in animals with EAE using a rectal probe.  Interestingly, 
the animals showed hypothermia at the ‘peak disease (PD)’ and ‘relapse (REL)’, and 
the temperature was 34°C and 34.3°C respectively (Figure 4.7), which was both 
significantly different from the temperature measured at ‘preinduction (PI)’ (36.5°C, 
P<0.001).  At ‘remission (REM)’, the temperature increased in these animals to a 
normal level (36.1°C, P<0.05, compared with ‘peak disease (PD)’).  In addition, when 
the rectal temperature was plotted against the neurological score, there was a 
significant negative correlation (Spearman r value= -0.84, P<0.0001) as shown in 
Figure 4.8. 
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Figure 4.7.  Rectal temperature along the time course of EAE 
Rectal temperature was measured in non-anaesthetised animals at five time points along the 
disease course of EAE (EAE (N=23), IFA (N=5), naїve (N=5)).  The animals showed a 
significant decrease of temperature at the ‘peak disease (PD)’ and ‘relapse (REL)’ compared 
with ‘preinduction (PI)’ (P < 0.001).  The temperature at remission ‘(REM)’was significantly 
higher (p<0.05) than both ‘peak disease (PD)’ and ‘relapse (REL)’ (P value was obtained 
by One way ANOVA, Newman-Keuls post test).  
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Figure 4.8.  Correlation between rectal temperature and neurological scores in animals with 
EAE 
Rectal temperature was measured in non-anaesthetised animals (N=17) with EAE.  A 
significant negative correlation was found between the rectal temperatures and neurological 
scores in these animals.  The Spearman r value was -0.84, and P<0.0001 (Spearman’s rank 
correlation test).  
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4.3.2.  Electrophysiological assessment 
 
For electrophysiological examinations, only animals that had gone through all the five 
key stages of EAE described in Table 4.2. were included for the final analysis.  Thirty 
animals were induced with EAE for the measurement of axonal conduction, motor 
neuronal excitability, and synaptic transmission, and among the induced animals, only 
21 rats matched the criteria for the final analysis (3 did not present neurological signs, 
4 died at the first peak of disease, 2 did not relapse after remission).  However, another 
new batch of 13 animals was induced with EAE separately for the analysis of synaptic 
activation of motor neurons, due to the time required for development of the technique.  
Among these animals, nine were included for analysis of the electrophysiological 
recordings (one had no signs, 2 died at the first peak, 1 died after remission). 
 
4.3.2.1.  Sensory compound action potential (SCAP) 
 
The antidromic sensory compound action potential (SCAP) was measured in animals 
with EAE at five stages along the disease course.  Using Excel software, the peak 
amplitude was measured in each recording, and a mean value was calculated per group.   
As shown in Figure 4.9 (a), the mean peak amplitude of EAE animals shown in red 
decreased significantly at ‘peak disease (PD)’ compared with ‘preinduction (PI)’, and 
it remained decreased until ‘relapse (REL)’ (P<0.001).  The mean peak response 
amplitude was 153.7µV, 142.9µV, 58.48µV, 34.9µV, 24.6µV at ‘preinduction (PI)’, 
‘predisease (PreD)’, ‘peak disease (PD)’, ‘remission (REM)’, ‘relapse (REL)’ 
respectively.  The representative recordings of SCAP at the five key stages are shown 
in Figure 4.9 (b), where the graphs are plotted from front to back chronologically 
(from ‘preinduction (PI)’ to ‘relapse (REL)’).   
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Figure 4.9.  Sensory compound action potentials (SCAP) measured in animals with EAE 
and controls (IFA, naїve) 
Sensory compound action potentials (SCAP) were measured at five stages along the disease 
course of animals with EAE (N=21) and controls (IFA, naïve, N=5 each).  
(a) The mean (±SE) SCAP amplitude was significantly reduced at the ‘peak disease (PD)’ and 
remained decreased until ‘relapse (REL)’ compared with ‘preinduction (PI)’ (P<0.001, One 
way ANOVA, Newman-Keuls post test).  
(b) Shows a representative waterfall plot of SCAP recorded at five stages of the disease course.  
Recordings are aligned from front to back chronologically (‘preinduction’ to ‘relapse’) 
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4.3.2.2.  H reflex, M response and F wave 
 
H reflexes, which are the result of a monosynaptic reflex, were measured at different 
stages along the disease course in animals with EAE.  The mean peak response 
amplitudes were measured using Excel software and plotted in Figure 4.10 (a).  The 
mean response amplitude of H reflex at ‘preinduction (PI)’ was 7.1mV and it 
decreased significantly only at ‘relapse (REL)’ (P<0.001) to 2.42mV.  Figure 4.10 (b) 
shows representative waterfall recordings of H reflexes taken at different stages, 
starting from ‘preinduction (PI)’ to ‘relapse (REL)’ aligned from front to back.  It 
shows that at the ‘relapse (REL)’, the H reflex was significantly reduced. 
 
When the stimulation was increased to a supramaximal level, the M responses and F 
waves were recorded.  The mean peak response amplitudes of M responses and F 
waves were plotted at five different stages in Figure 4.10 (c) and (d) respectively. 
Similar to the H reflexes, F waves were only significantly reduced at ‘relapse (REL)’ 
at a mean value of 1.84mV.  However, the M response was decreased significantly, 
earlier than H reflex or F waves during ‘remission (REM)’ to ‘relapse (REL)’ 
(P<0.001).  The representative recordings of M responses and F waves taken at each of 
the five key time points along the disease course are aligned as a waterfall plot in 
Figure 4.10 (e).   
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Figure 4.10.  H reflex, M response and F wave measured in animals with EAE and controls 
(IFA, naїve) 
The H reflex, M response and F wave were measured at the five key stages of disease of 
animals with EAE (N=21) and controls (IFA, naïve, N=5 each).   
(a)  H reflex was measured in animals at five different stages, and the means (±SE) were 
plotted.  A significant reduction of the response amplitude was only seen at ‘relapse (REL)’ 
compared with ‘preinduction (PI)’ (P<0.001, One way ANOVA, Newman-Keuls post test). 
(b)  A representative waterfall plot of M response and H reflex recordings at different stages of 
EAE are illustrated in a chronological order from front to back (‘preinduction’ to ‘relapse’). 
(c) ,(d)  Means (±SE) of M responses and F waves are plotted respectively.  The F waves were 
reduced significantly only at ‘relapse (REL)’ (P<0.001), whereas the M response was reduced 
from ‘remission (REM)’ until ‘relapse (REL)’ (P<0.001).  P value obtained by One way 
ANOVA, Newman-Keuls post test. 
(e)  A representative waterfall plot of M responses and F waves recorded at the key stages 
along the disease course of EAE is shown sequentially, aligned in chronological order. 
 
 
 
 
 
99 
 
4.3.2.3.  Cord dorsum potential (CDP) 
 
Cord dorsum potentials (CDP) were measured in animals with EAE and the peak 
response amplitudes of these dorsal horn synaptic responses were plotted as line 
graphs, shown in Figure 4.11 (a).  At ‘preinduction (PI)’, the mean dorsal horn 
synaptic response was 74.89µV, and this response was significantly reduced at the 
‘peak disease (PD)’ (58.98µV, P<0.01), ‘remission (REM)’ (57.98µV, P<0.01) and 
also at ‘relapse (REL)’ (45.78µV, P<0.001).  Figure 4.11(b) illustrates each recording 
taken at five time stages, aligned sequentially from front to back.  
 
4.3.2.4.  Synaptic activation of motor neurons (SAM) 
 
The response amplitude of the synaptic activation of motor neurons (SAM) was 
measured and plotted in line graphs as shown in Figure 4.12 (a).  There was a 
noticeable significant decrease of SAM at ‘peak disease (PD)’, where the response 
amplitude was 2.16mV compared to 9.92mV at ‘preinduction (PI)’ (P<0.001).  
Although there was a slight increase of SAM at ‘remission (REM)’, the difference was 
not significant.  At ‘relapse (REL)’, the SAM was almost absent, and the mean value 
was 0.09mV (significantly decreased, P<0.001).  Figure 4.12 (b) illustrates 
representative recordings of SAM at five different stages sequentially, in chronological 
order from front to back. 
 
 
 
 
 
100 
 
** 
** 
 
0
40
60
80
100
EAE
IFA
NAIVE
Stages of EAED
o
rs
al
 
ho
rn
 
sy
n
ap
tic
 
am
pl
itu
de
 
(µµ µµ
V)
PI PreD PD REM REL
       
 
 
 
 
 
 
 
*** 
A 
B 
PI 
PreD 
PD 
REM 
REL 
101 
 
 
 
 
 
 
 
Figure 4.11.  Cord dorsum potentials (CDP) measured in animals with EAE and controls 
(IFA, naїve) 
The CDPs were recorded at the five key stages along the disease course of animals with EAE 
(N=21) and controls (IFA, naïve, N=5 each).   
(a)  The means (±SE) of the dorsal horn synaptic response amplitudes were plotted and show 
that a significant reduction of the response amplitude was observed at ‘peak disease (PD)’ 
(P<0.01), ‘remission (REM)’ (P<0.01), and at ‘relapse (REL)’ (P<0.001) compared with 
‘preinduction (PI)’(P value obtained by One way ANOVA, Newman-Keuls post test).   
(b)   Representative waterfall plot of CDP taken at each of the five key stages of EAE, aligned 
sequentially in chronological order from front to back (‘preinduction’ to ‘relapse’). 
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Figure 4.12.  Synaptic activation of motor neuron (SAM) measured in animals with EAE 
and controls (IFA, naїve) 
SAM was measured at the five key stages along the disease course of animals with EAE (N=9) 
and controls (IFA, naïve, N=5 each).   
(a)  The means (±SE) of SAM were plotted and show that a significant reduction of the 
response amplitude was observed from ‘peak disease (PD)’ to ‘relapse (REL)’ (P<0.001, One 
way ANOVA, Newman-Keuls post test) compared with ‘preinduction (PI)’.   
(b)   Representative waterfall plot of SAM taken at five different stages is aligned sequentially 
in chronological order from front to back (‘preinduction’ to ‘relapse’). 
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4.3.2.5.  Summary of the electrophysiological changes in the disease course 
of EAE 
 
Table 4.5 below summarises the electrophysiological changes at the five key stages of 
EAE.  At the ‘peak disease (PD)’, axonal conduction (SCAP), synaptic transmission 
(CDP) and synaptic activation of motor neurons (SAM) were all significantly reduced.  
These measures remained reduced during ‘remission (REM)’ and ‘relapse (REL)’, at 
which time motor neuronal excitability (H reflex, M response, and F wave) was also 
significantly decreased.  Surprisingly, none of the measures showed an increase upon 
remission from the deficits.   
     
 
Table 4.5.  Table summarising electrophysiological changes along five different 
stages of EAE                          
 Preinduction 
(PI) 
Predisease 
(PreD) 
Peak Disease 
(PD) 
Remission 
(REM) 
Relapse 
(REL) 
SCAP – – *** *** *** 
M response – – – *** *** 
H reflex – – – – *** 
F wave – – – – *** 
CDP – – ** ** *** 
SAM – – *** *** *** 
Note: symbols are used to indicate * P<0.05, ** P<0.01, ***P<0.001, - no significant change 
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4.3.3.  Histological assessment 
 
Histological changes in the spinal cord at different stages along the disease course of 
EAE were explored (three animals at each stage).  A total of twelve animals were 
induced with EAE, and the neurological scores of  these animals are plotted in Figure 
4.13, where the five groups are colour coded (‘preinduction (PI)’ in black, ‘predisease 
(PreD)’ in orange, ‘peak disease (PD)’ in red,’ remission (REM)’ in green, ‘relapse 
(REL)’ in blue).  This graph shows that animals for ‘preinduction (PI)’ were culled 
before induction of the disease, and animals for ‘predisease (PreD)’ were culled at day 
five post induction.  Animals for ‘peak disease (PD)’, were culled at day 9,10 and 11 
post induction, and all of these animals showed paralysis of both limbs (i.e. a 
neurological score of nine).  The animals that were used for ‘remission (REM)’ 
reached a neurological score of nine at their ‘peak disease (PD)’, and recovered 
eventually to a score of three.  Also, animals for ‘relapse (REL)’ had reached their 
second peak between day 15 and 17 post induction.  The selection procedure of these 
animals for histology fulfilled the criteria listed in Table 4.2.  For control tissue, IFA 
animals were culled at the same time points with the EAE animals (N=3 in each group).  
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Figure 4.13.  Neurological scores of animals for histological analysis  
Neurological scores of animals used for histological assessments are plotted  against time in 
days following the ‘induction of EAE’ (N=3 in each group).  These groups are colour-coded 
as follows;  ‘preinduction (PI); black’, ‘predisease (PreD); orange’, ’peak disease (PD); red’, 
‘remission (REM); green’, and ‘relapse (REL); blue’.  The animals were selected according to 
the criteria described in Table 4.2 and cullled for histological analyses. 
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4.3.3.1.  Microglial/macrophage activation (ED1 labelling) 
 
Immunoreactivity for ED1 was assessed quantitatively by calculating the percentage 
area of labelling in transverse sections of the spinal cord of animals at the key stages of 
EAE.  No ED1 expression was observed at ‘preinduction (PI)’ and ‘predisease (PreD)’, 
(Figure 4.14).  However, ED1 expression was significantly increased at ‘peak disease 
(PD)’ to 6% (P<0.05), and at ‘relapse (REL)’ to 5.87% (P<0.05), compared with 
‘preinduction (PI)’.  Figure 4.15 (e) shows the cord labelled with ED1 at the ‘peak 
disease (PD)’, where clustered ED1 positive cells were mostly found in the subpial and 
perivascular regions. At ‘remission (REM)’, the degree of labelling was decreased to 
2.41%, and the pattern of labelled cells was similar to ‘peak disease (PD)’ (Figure 4.15 
(g)).  At ‘relapse (REL)’ the degree of labelling was increased to a mean of 5.87%, but 
ED1 positive cells were mostly accumulated in the white matter rather than the grey 
(Figure 4.11 (i)).  None of the control animals showed immunoreactivity for ED1.  
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Figure 4.14.  ED1 expression in percentages at different stages of EAE 
ED1 immunoreactivity was quantified by calculating the percentage area of labelling in the 
spinal cords of animals with EAE and controls (IFA) (N=3 in each stage).  ED1 expression 
was significantly increased at ‘peak disease (PD)’ and ‘relapse (REL)’ compared with 
‘preinduction (PI)’ (P<0.05, One way ANOVA, Newman-Keuls post test).   
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Figure 4.15.  ED1 labelling of spinal cord sections at different stages of EAE  
Transverse sections of the spinal cords were taken from animals at the key stages of EAE, and 
were labelled immunohistochemically for the presence of ED1.  The sections in the left and 
right columns are taken from EAE and control (IFA) respectively.   
(a) and (b) are spinal cords at ‘preinduction (PI)’, (c) and (d) are at ‘predisease (PreD)’,  (e) 
and (f) are at ‘peak disease (PD)’, (g) and (h) are at ‘remission (REM)’, (i) and (j) are at 
‘relapse (REL)’.  In animals with EAE, ED1 immunoreactivity was significantly increased at 
‘peak disease (PD)’ especially around subpial and perivascular regions of the spinal cord.  At 
‘remission (REM)’, the level of ED1 staining was decreased compared with ‘peak disease 
(PD)’.  However at ‘relapse (REL)’, the degree of labelling was increased showing 
concentrated immunoreactivity in the white matter compared to the grey.  (Scale 
bar=1000µm) 
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As it was observed that the immunoreactivity of ED1 was positive mainly during the 
period when the animals showed neurological signs (i.e. at ‘peak disease (PD)’, 
‘remission (REM)’ and ‘relapse (REL)’), the correlation between ‘ED1 labelling’ and 
‘neurological scores’ was analysed.  Figure 4.16 shows that there was a significant 
correlation (p<0.0001, R2=0.81) between the two values. 
 
 
       
1 2 3 4 5 6 7 8 9 10
-1
0
1
2
3
4
5
6
7
8
9
Neurological scores
ED
1 
la
be
lli
n
g 
(%
)
 
 
Figure 4.16.  Correlation of ED1 labelling and neurological scores  
ED1 labelling (%) and neurological scores of animals with EAE show significant positive 
correlation (N=15). The Spearman r value was 0.9, and P<0.0001 (Spearman’s rank 
correlation test).  
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4.3.3.2.  iNOS labelling 
 
Immunoreactivity for iNOS was assessed quantitatively by measuring the percentage 
area of labelling in transverse spinal cord sections of animals at different stages of 
EAE.  The results are plotted in Figure 4.17.  The expression of iNOS was exclusively 
detected at the ‘peak disease (PD)’ stage of EAE, and it showed a mean of 1.2% of 
spinal cord area. The pattern of expression was similar to the expression of ED1 
observed at the same stage, as iNOS labelling was found mostly around subpial and 
perivascular regions (Figure 4.18 (e)).  No animals at other stages of the disease, or 
controls showed, iNOS positivity.   
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Figure 4.17.  iNOS labelling of spinal cord sections at different stages of EAE  
iNOS expression was quantitatively analysed using animals at different stages of EAE (N=3 in 
each stage).  The expression was exclusive at ‘peak disease (PD)’, where labelling was a mean 
of 1.2% of the whole spinal cord area. 
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Figure 4.18.  iNOS labelling of spinal cord sections at different stages of EAE  
Transverse sections of the spinal cords were taken from animals at the key stages of EAE, and 
were labelled immunohistochemically for the presence of iNOS.  The sections in the left and 
right columns are taken from EAE and control (IFA) respectively.   
(a) and (b) are spinal cords taken at ‘preinduction (PI)’, (c) and (d) are at ‘predisease (PreD)’,  
(e) and (f) are at ‘peak disease (PD)’, (g) and (h) are at ‘remission (REM)’, (i) and (j) are at 
‘relapse (REL)’.  In EAE tissue, iNOS immunoreactivity was exclusively expressed at ‘peak 
disease (PD)’, and the labelling occurred in the subpial and perivascular regions.  (Scale 
bar=1000µm) 
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4.3.2.3.  Degeneration and demyelination  
 
Pathology of the white matter was quantified in animals with EAE at different stages, 
using resin sections of the same animals used for immunohistochemistry.  The 
pathology included areas of both axonal degeneration and demyelination.  At 
‘preinduction (PI)’ and ‘predisease (PreD)’, no pathology was observed in any of the 
tissues (Figure 4.19 and Figure 4.20 (a), (c)).  However, a mean area of 16.5% of the 
white matter was affected at ‘peak disease (PD)’ (P<0.001 compared with PI), and the 
pathology was mostly present around the rim of the spinal cord, perivascular regions 
and the dorsal column (Figure 4.20 (e)).  At ‘remission (REM)’, less pathology was 
found than at ‘peak disease (PD)’ where the mean value was 6.4%, occurring in the 
similar areas (Figure 4.20 (g)).  The pathology at ‘relapse (REL)’ was widespread 
(P<0.001 compared with PI), covering more than half of the white matter (mean was 
58.9%, Figure 4.20 (i)).  None of the animals injected with IFA showed pathological 
changes.   
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Figure 4.19.  Percentage of pathology in white matter at different stages of EAE 
Pathological area of the white matter of the spinal cord was measured in animals with EAE, at 
different stages (N=3 in each stage).  No pathology was observed at ‘preinduction (PI)’ and 
‘predisease (PreD)’, but a significant amount of pathology was found at the ‘peak disease 
(PD)’ (16.5%, P<0.05) compared with ‘preinduction (PI)’.  At ‘relapse (REL)’ the percentage 
area of pathology significantly increased to 58.9% (compared with ‘preinduction (PI)’ and 
‘remission (REM)’ (P<0.001).  (P value was obtained by One way ANOVA, Newman-Keuls 
post test).   
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Figure 4.20.  Resin sections of spinal cord at different stages of EAE 
Transverse sections of the spinal cord were taken from animals at the five key stages of EAE, 
and were processed into resin sections.  The sections in the left and right columns are taken 
from EAE and control (IFA) respectively.   
(a) and (b) are spinal cords taken at ‘preinduction (PI)’, (c) and (d) are at ‘predisease (PreD)’,  
(e) and (f) are at ‘peak disease (PD)’, (g) and (h) are at ‘remission (REM)’, (i) and (j) are at 
‘relapse (REL)’.  In EAE animals, a significant increase in pathology was observed at ‘peak 
disease (PD)’ compared with ‘preinduction (PI)’ (P<0.05), including both axonal 
degeneration and demyelination which were found at the rim of the spinal cord, perivascular 
regions and dorsal column.  Animals at ‘remission (REM)’ also showed pathology in the same 
regions, but the amount of pathology was reduced.  At ‘relapse (REL)’, the pathology was 
more widespread, affecting more than half of the white matter.  (Scale bar=1000µm)  
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Further investigations of the pathological changes in the dorsal column of the spinal 
cords were performed, in order to study the correlation with axonal conduction 
measured from the dorsal column axons.  The pathology was quantified by adding the 
areas of both demyelination and axonal degeneration.  Figure 4.21 (a) shows that there 
was no pathology observed at either ‘preinduction (PI)’ or ‘predisease (PreD)’.  
However, at the remaining stages of the disease, the percentage of pathology showed a 
biphasic pattern.  At the ‘peak disease (PD)’, the mean percentage was 83.33%, which 
was significantly higher than at ‘preinduction (PI)’ (P<0.001).  At ‘remission (REM)’, 
the percentage decreased to a mean of 36.4%, and at ‘relapse (REL)’ the mean 
percentage increased to 96.67% (P<0.001).   In these tissues, the composition of the 
pathology (ratio of degeneration and demyelination) was different as shown in Figure 
4.21 (b).  Axonal degeneration was more prominent than demyelination in tissues 
collected at ‘peak disease (PD)’ (a photomicrograph is presented in Figure 4.22 (e)), 
but demyelination became dominant at ‘remission (REM)’ (Figure 4.22 (g)).  However, 
at ‘relapse (REL)’, the pathology showed a similar amount of each of these two factors 
(Figure 4.22 (i)).   
 
Using the area of pathology of the dorsal columns, the correlation between the 
pathology and axonal conduction was explored.  Axonal conduction was measured by 
recording the SCAP, and the response amplitudes of SCAP at different stages are 
plotted in Figure 4.23 (a).  The SCAP was significantly decreased at ‘peak disease 
(PD)’ (P<0.001) and remained decreased until ‘relapse (REL)’ (P<0.001), which was 
reminiscent of the SCAP recordings shown previously with a larger number of rats 
(Figure 4.9).  However, the dot plot in Figure 4.23 (b) illustrates that there was no 
significant correlation between the axonal conduction and area of pathology in the 
dorsal columns. 
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Figure 4.21.  Pathology in the dorsal columns at different stages of EAE 
(a)  The percentage of total pathology in the dorsal columns was measured and plotted at the 
five key stages of the disease (N=3 in each stage).  No pathology was found at ‘preinduction 
(PI)’ and ‘predisease (PreD)’.  However, significant amount of pathology was found at ‘peak 
disease (PD)’ and ‘relapse (REL)’ (P<0.001, One way ANOVA, Newman-Keuls post test).  
The mean percentage of pathology at each stage was 83.33%, 36.4%, and 96.67% at ‘peak 
disease (PD)’, ‘remission (REM)’ and ‘relapse (REL)’ respectively.    
(b)  The areas of axonal degeneration and demyelination were measured and plotted as 
percentages at each stage of the disease (N=3 in each stage).  Degeneration was dominant at 
‘peak disease (PD)’, but demyelination was dominant at ‘remission (REM)’. At ‘relapse 
(REL)’, these two factors were more balanced. 
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Figure 4.22.  Dorsal columns at different stages of EAE 
Transverse sections of the dorsal columns were taken from animals at the five key stages along 
the disease course of EAE.  The sections in the left and right columns are taken from EAE and 
control (IFA) respectively.   
(a) and (b) are spinal cords taken at ‘preinduction (PI)’, (c) and (d) at ‘predisease (PreD)’, (e) 
and (f) are at ‘peak disease (PD)’, (g) and (h) are at ‘remission (REM)’, (i) and (j) are at 
‘relapse (REL)’.  In EAE tissues, a significant increase of pathology was observed at ‘peak 
disease (PD)’, where axonal degeneration was more prominent than demyelination.  However, 
the amount of degeneration decreased at ‘remission (REM)’ and the pathology was mostly 
composed of demyelination.  At ‘relapse (REL)’, the amount of both degeneration and 
demyelination were similar in the dorsal column.  (Scale bar=250µm) 
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Figure 4.23.  Sensory compound action potentials (SCAP) measured in animals used for 
histology, and their correlation with dorsal column pathology 
(a)  Sensory compound action potentials (SCAP) were measured at the key stages of EAE in 
the same animals that were used for histology (N=3 in each stage).  The amplitude of the 
SCAP was significantly decreased from ‘peak disease (PD)’ until ‘relapse (REL)’ (P<0.001, 
compared with ‘preinduction (PI)’, One way ANOVA, Newman-Keuls post test).  
(b)  There was no significant correlation between the ‘response amplitude of SCAP’ and 
‘percentage of dorsal column pathology’ (N=8) in animals with EAE. (Spearman r value was 
0.01, and P =0.96 by Spearman’s rank correlation test) 
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4.4.  Conclusion 
 
The neurological, electrophysiological and histological analyses were performed to 
understand the mechanisms underlying relapses and remissions, in animals with EAE.  
In these animals, hypothermia was found in association with worsening of the 
neurological signs and limb function at ‘peak disease’ and ‘relapse’, and further 
investigation is required to understand the cause.   
 
Electrophysiological analysis showed that axonal conduction and synaptic 
transmission were impaired from the ‘peak disease’ until ‘relapse’, and motor neuronal 
excitability was also impaired at ‘relapse’.  It is surprising that none of the measures 
recovered at ‘remission’, which implies that there could be other factors responsible 
for the deficits in these animals.  Also, histological methods were used to identify any 
inflammatory factors which may correlate with the neurological deficits, such as 
activation of macrophages/microglia or iNOS expression.  Significantly increased ED1 
expression was found at both ‘peak disease’ and ‘relapse’, but iNOS was specifically 
expressed at the ‘peak disease’.  Pathological changes were also quantified using resin 
sections, but no correlation was found between the axonal conduction and pathology in 
the dorsal columns. 
 
The specific expression of iNOS observed during the first peak of disease lead us to 
focus on nitric oxide (NO), which has been implicated in MS and EAE by our and 
other laboratories.  Thus, I planned to administer a selective iNOS inhibitor (1400W) 
in these animals to explore whether it inhibited the expression of neurological deficits.  
The results are described in the following chapter five. 
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Chapter 5 
Understanding mechanisms underlying relapses and 
remissions by modulation of inflammatory factors 
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Chapter 5.  Understanding mechanisms underlying relapses and remissions 
by modulation of inflammatory factors 
5.1.  Introduction and aims 
 
It has become clear that neurological deficits in multiple sclerosis (MS), such as 
paralysis, blindness and numbness, can arise not only from the demyelination that is 
characteristic of the disease, but also from the accompanying inflammation, even in the 
absence of demyelination.  However, the mechanisms responsible remain unclear. 
   
The aim of this chapter was to investigate whether modulating inflammatory factors 
could affect the disease course of EAE.  Firstly I explored whether inducing systemic 
inflammation by administering lipopolysaccharide (LPS) systemically in animals with 
EAE in their ‘remission (REM)’ stage, exacerbates the disease causing relapse.  Since 
LPS is a bacterial endotoxin which elicits strong innate immune response within the 
injected animals (Marshall 2005), we hypothesised that this pro-inflammatory agent 
may induce an inflammatory exacerbation in the animals with EAE, therefore 
providing us with a model for studying the possible mechanisms underlying the 
relapse by using neurological, and electrophysiological techniques.  An exacerbation 
of EAE caused by LPS has been described by Hugh Perry’s group (public 
communication), but according to our Pubmed search, it appears that the method has 
not been published in the years since its description. 
Secondly, a selective iNOS inhibitor 1400W was administered to animals with EAE at 
their onset of disease expression to examine whether iNOS inhibition ameliorates 
neurological signs and protects axonal function.  This experiment is based on the 
finding previously described in Results Chapter 4, where iNOS immunoreactivity was 
expressed exclusively at the ‘peak disease (PD)’.  Neurological, electrophysiological 
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and histological assessments were used in this study and any differences between the 
drug treated group and controls were noted.  
 
5.2.  Methods 
 
5.2.1.  Animals and anaesthesia 
 
The methods have been previously described in Chapter 3, Methods 3.2.1 and 3.2.2. 
Animals that reached a neurological score of more than five, were provided with 
mashed food. 
 
5.2.2.  Systemic injection of lipopolysaccharide (LPS) in animals with EAE 
 
EAE was induced in DA rats as described in Chapter 4, Methods 4.2.3.  When these 
animals reached ‘remission (REM)’ (selection criteria described in Table 4.2.), the 
animals were given an injection of lipopolysaccharide (LPS, Sigma Aldrich, St Louis, 
USA, 1mg/kg dissolved in saline) into their saphenous vein using a 0.5 mL insulin 
syringe (Terumo, MD21921, USA).  
  
5.2.3.  Administration of 1400W in animals with EAE  
 
Animals induced with EAE that reached a score of two or three (around day eight to 
eleven post immunisation) were paired for similarity of deficit, and either a selective 
iNOS inhibitor 1400W (Enzo Life Sciences (UK) Ltd., Exeter, UK, 10mg/kg/day, 
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dissolved in saline) or vehicle (saline) was administered intraperitoneally, for seven 
days.  The animals were monitored daily by neurological assessment, and were culled 
at the last day of administration for electrophysiological and histological examinations. 
5.2.4.  Rectal temperature monitoring, and neurological assessment  
 
The rectal temperature was monitored by a temperature probe as described in Chapter 
4, Methods 4.2.2.  Neurological assessment was performed according to the ten point 
scale introduced in Methods 4.2.4. 
 
5.2.5. Behavioural assessment by inclined plane measurements 
 
Behavioural assessments were performed by measuring the maximum angle that the 
animal could sustain on an inclined plane, as described in Chapter 4, Methods 4.2.5. 
 
5.2.6.  Electrophysiological assessment 
 
Sensory compound action potential (SCAP), H reflex, F wave, M response, and cord 
dorsum potentials (CDP) were examined in animals injected with LPS.  The sensory 
compound action potential (SCAP) was examined in animals that were used for the 
iNOS inhibition experiment.  Methods for these electrophysiological examinations are 
described in Chapter 3, Methods section 3.2.3. 
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5.2.7. Histological assessment 
 
Cardiac perfusion (Methods 3.2.4.1.) with fixative (paraformaldehyde) was performed 
in animals treated with 1400W/vehicle (saline) on the last day of administration.  A 
laminectomy was performed and the spinal cords were removed and processed for 
resin sections (Method 3.2.4.2.).  Image J software (Rasband, W.S., ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 
1997-2009) was used to draw around, and measure, the area of pathology in images of 
the spinal cord taken using light microscopy. 
 
5.2.8.  Statistics 
 
Data were expressed with means and standard deviations, and plotted using   
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, USA). 
One-way ANOVA with Newman-Keuls post test was performed to compare the means 
in three or more groups, and Paired T test was performed to compare the means of two 
groups.  ‘Statistical significance’ was determined by the p value obtained from these 
tests.  (P<0.05 (*), P<0.01 (**), P<0.001 (***)) 
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5.3. Results 
 
5.3.1.  Induction of systemic inflammation by LPS injection 
  
5.3.1.1.  Neurological and behavioural assessments 
 
Animals which received an intravenous injection of LPS at ‘remission (REM)’ stage 
showed significantly increased neurological scores (+2.5, P<0.05), which peaked at 3.5 
hours post injection (Figure 5.1(a)).  This exacerbation had ameliorated by 30 hours 
post injection.  Also, the inclined plane test showed that there was a significant 
decrease in motor function (P<0.01) at the time when the neurological score peaked in 
these animals (Figure 5.1(b)).  Surprisingly, hypothermia was associated with the 
exacerbation, showing a 1.4 °C decrease at 3.5 hours post injection (P<0.01), which 
was recovered to normal with the amelioration in neurological deficit (Figure 5.1(c)).  
These results are reminiscent of data shown in Figure 4.7. in chapter four, where rectal 
temperature was significantly low at ‘peak disease (PD)’ and ‘relapse (REL)’, when 
the neurological scores were significantly low. 
 
5.3.1.2.  Electrophysiological assessments 
 
Electrophysiological examination was performed in order to examine the possible 
mechanism underlying the exacerbation of the disease in EAE animals receiving LPS.  
Sensory compound action potentials (SCAP),  H reflex, F wave and cord dorsum 
potential (CDP) were recorded at ‘remission (REM)’, ‘peak of exacerbation after 
injection of LPS (at 3.5 hours post injection, LPS)’ and ‘recovery from  the peak (at 30 
hours post injection, REC)’.  However, none of the electrophysiological properties 
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showed any significant changes (Figure 5.2), and thus none could explain the 
mechanism of exacerbation responsible for the LPS-induced relapse. 
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Figure 5.1. Examination of neurological score, inclined plane measurements, and rectal 
temperature after injection of LPS in animals with EAE at ‘remission (REM)’ 
(a)  Exacerbation of disease was observed in animals after the injection of LPS, which peaked 
at 3.5 hours post injection (N=6 in each group).  Neurological score was significantly 
increased by 2.5 (P<0.05, One-way ANOVA and Newman-Keuls post test) at this time 
point. 
(b)  Inclined plane angle measurement was also decreased significantly at the peak of 
exacerbation (P<0.01, One-way ANOVA and Newman-Keuls post test). 
(c)  Rectal temperature also decreased in association with the exacerbation (P<0.01, One-
way ANOVA and Newman-Keuls post test).  All of these measures recovered by 30 hours 
post injection. 
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Figure 5.2. Electrophysiological changes in animals injected with LPS 
Electrophysiological examination was performed in animals with EAE at ‘remission (REM)’, 
‘peak of exacerbation after injection of LPS (at 3.5 hours post injection, LPS)’ and ‘recovery 
from the peak (at 30 hours post injection, REC)’, (N=5 in EAE, N=3 in control (saline)).  
There were no significant changes observed in the response amplitude measured in (a) sensory 
compound action potential (SCAP), (b) H reflex, (c) F wave, (d) M response, and (e) cord 
dorsum potential (CDP). 
A B 
C D 
E 
SCAP H reflex 
F wave M response 
CDP 
137 
 
5.3.2.  Inhibition of iNOS by a selective iNOS inhibitor 1400W 
 
5.3.2.1.  Neurological assessment 
 
The iNOS inhibitor 1400W or vehicle (saline) were administered at the onset of 
disease in 8 pairs of animals paired for their similarity of neurological deficit induced 
with EAE, when they reached a score of two to three (i.e. reduction of muscle tone, or 
paralysis of the tail, which occurred around day 8 to 11 post immunisation).  On the 
first day of administration, the animals were monitored every hour for six hours, but 
did not show any improvement or worsening of the neurological signs (data not 
shown).  However, a day afterwards, a significant difference (P<0.05) was present 
between the neurological scores of the two groups, and on day two post administration, 
the animals showed the biggest difference between the neurological scores (P<0.001) 
(Figure 5.3).  At this time point, most of the animals treated with vehicle (seven out of 
eight) reached a peak score of nine, with paralysed hindlimbs (mean score was 9), 
whilst only one out of eight animals receiving 1400W reached a score of nine (mean 
score 6.37, apart from one animal, the rest did not get paralysed).  In addition, the 
vehicle-treated animals reached their peak scores at two days after administration, 
however, the drug-treated animals reached their peak a day later.  The animals in both 
groups showed a recovery after reaching their peaks, and they showed similar 
neurological scores at day five post administration.  On day six post administration, 
sensory compound action potentials (SCAP) were recorded from all of the animals, 
followed by perfusion for histological analysis.  To assess the effectiveness of the drug, 
the neurological score inhibited at the peak and at termination were averaged and 
compared between the two treatment groups (Figure 5.4(a),(b)).  Although there was 
no difference at termination, the peak neurological score showed a significant 
difference (P<0.01), where the mean scores of drug-treated animals and vehicle-treated 
animals were seven and nine respectively.   
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Figure 5.3.  Neurological scores of the animals with EAE administered with 1400W/vehicle 
(saline) 
The animals were paired for expression of neurological deficit at the onset of the disease of 
EAE, when they reached a neurological score of two to three, and were administered with 
either drug (1400W) or vehicle (saline) for seven days (N=8 in each group).  The animals 
were assessed by neurological scoring daily.  Vehicle- and drug- treated animals showed the 
peak of disease at day 2 and day 3 post administration respectively.  The neurological scores 
between the two groups were significantly different from day one (P<0.05) to three (P<0.001) 
post administration (Paired T test). 
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Figure 5.4.  Neurological scores at peak of disease, and at termination, in animals with EAE 
treated with 1400W and vehicle (saline) 
(a) The means (±SE) of neurological scores at the peak of disease in drug- and vehicle- treated 
animals are shown as bar graphs (N=8 in each group).  The mean neurological scores of 
drug- and vehicle- treated animals were 7 and 9 respectively, which were significantly 
different (P<0.01, paired T test). (b) shows means (±SE) of neurological scores of each group 
at the day of termination.  The mean score was similar between the two groups, being 5.87 and 
6.37 in drug- and vehicle- treated animals respectively.  
A 
B 
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5.3.2.2.  Electrophysiological assessment 
  
The sensory compound action potential (SCAP) was recorded at the day of termination 
(day six post administration) under ketamine/xylazine anaesthesia.  The peak SCAP 
amplitude was measured to assess the number of conducting axons in these animals.  
No SCAP was detectable in any of the animals treated with vehicle, whereas animals 
that received 1400W showed a mean response amplitude of 24.39µV (Figure 5.5 
shows the representative recordings).   
 
5.3.2.3.  Histological assessment 
 
Following electrophysiological examination, the animals were perfused for 
histological analysis.  The percentage of white matter pathology was calculated in a 
section from each animal using computer software (Image J), and the means of the two 
groups were compared.  The mean percentage of pathology measured in the white 
matter was similar in each group (26.7% and 23.5% in 1400W- and vehicle- treated 
animals respectively) as shown in Figure 5.6.  Representative images of each group are 
shown in Figure 5.8. ((a) 1400W treated, (c) vehicle treated), and they exhibit a similar 
amount of pathology in their white matter.  However, when the percentage of axonal 
degeneration and demyelination were compared within the measured pathological area 
of dorsal columns, the animals treated with 1400W showed significantly lower 
percentage of axonal degeneration (P<0.05) and higher demyelination (P<0.05) 
compared with the controls (Figure 5.7).   
 
 
 
 
141 
 
 
 
 
 
 
Figure 5.5.  Sensory compound action potential (SCAP) in animals with EAE treated with 
1400W and vehicle (saline) 
On day six post administration of agents, the animals were anaesthetised for examination of 
axonal conduction by measuring the peak response amplitude of SCAP (N=8 in each group).  
Black and red recordings are averages of all the SCAP recordings of animals with EAE 
treated with vehicle and drug respectively.  The mean response amplitude of SCAP in vehicle- 
and drug- treated animals was 0 µV and 24.39 µV respectively. 
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Figure 5.6.  Percentage of white matter pathology in animals treated with 1400W and 
vehicle (saline) 
The mean percentage area of pathology in the white matter was similar in the two groups :  
26.7% and 23.5% in 1400W- and vehicle- treated animals respectively (N=8 in each group). 
 
 
When the area of axonal degeneration, and of demyelination were separately measured 
in the dorsal column of these animals, a noticeable difference was observed.  Animals 
with 1400W treatment showed significantly less axonal degeneration, and more 
demyelination (both show P<0.05 by Paired T test), compared with vehicle- treated 
animals, as shown in Figure 5.7.  The representative images of the dorsal columns are 
presented in Figure 5.8 ((b) 1400W- treated, (d) vehicle- treated).   
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Figure 5.7.  Comparison of degeneration vs demyelination in the dorsal columns of animals 
treated with 1400W and vehicle (saline) 
The percentages of axonal degeneration and demyelination in the dorsal columns were 
measured in animals treated with 1400W or vehicle (saline) (N=8 in each group).  A 
significantly lower percentage of axonal degeneration, and a higher percentage of 
demyelination were observed in 1400W- treated animals compared with vehicle- treated 
(P<0.05, Paired T test).   
 
 
 
 
* 
* 
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Figure 5.8. Representative images of spinal cords, and corresponding dorsal columns, of 
animals treated with 1400W and vehicle (saline) 
(a) and (b) show transverse sections of spinal cord of  animals treated with 1400W or vehicle 
(saline) respectively, and they exhibit similar amounts of white matter pathology.  However, 
the dorsal column of these spinal cords showed a different composition of pathology (shown in 
(b) and (d) (magnified images of the red inset shown in (a) and (b) respectively)).  The dorsal 
columns of the animals treated with vehicle (d) showed more axonal degeneration than 
demyelination compared with animals treated with 1400W (b). 
(Black scale bar=1000µm, white scale bar=250µm) 
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5.4.  Conclusion 
 
The results described in this chapter show that the systemic administration of the pro-
inflammatory agent LPS in animals with EAE at their ‘remission’, causes an acute 
relapse that peaks 3.5 hours post injection.  This exacerbation was associated with 
impaired motor function and hypothermia.  The hypothermia was reminiscent of that 
exhibited in EAE animals at the ‘peak disease’, and at ‘relapse’.  It is surprising that 
none of the electrophysiological changes observed could easily explain the 
mechanisms responsible for these deficits.  In addition, animals that were administered 
with a selective iNOS inhibitor 1400W showed significantly decreased neurological 
scores at their peak, and the peak appeared a day later than in control animals.  Also, 
the number of functional axons measured by recording the sensory compound action 
potentials (SCAP) in these animals was enhanced compared with controls.  Moreover, 
although the percentage area of pathology in the white matter measured in the two 
groups was similar, axonal degeneration was significantly less prominent in 1400W- 
treated animals, which implies that 1400W may protect axons from degeneration, but 
not necessarily from demyelination. 
 
Collectively the results show that inflammation may play an important role in the 
development of neurological signs in EAE, and that iNOS inhibition could be used as a 
potential therapy for MS. 
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Chapter 6.  Discussion 
6.1.  Optimisation of electrophysiological techniques  
 
Together with MRI techniques, electrophysiological examinations have been used for 
diagnosing and evaluating the clinical disease course in patients with MS (Fuhr and 
Kappos 2001;Kallmann et al. 2006).  It has been reported from Waxman et al that a 
combination of visual evoked potentials (VEPs), somatic sensory evoked potentials 
(SEPs) and brain stem auditory evoked potentials detected subclinical lesions in 
patients, which later were confirmed to have a diagnosis of MS (Waxman 1988).  Also, 
patients showing evoked potential (EP) abnormalities had a 71% higher risk of clinical 
deterioration compared with others having normal EPs (Hume and Waxman 1988).  As 
implied in these studies, electrophysiological assessments can be useful in the 
diagnosis of the disease in MS patients, and indeed a correlation of EP data with scores 
on the expanded disability status scale (EDSS) was described in several studies (Salle 
et al. 1992;O'Connor et al. 1998;Fuhr et al. 2001;Kallmann et al. 2006).  In particular, 
Kallmann et al reported that EPs recorded within two years after the disease onset of 
MS correlated with EDSS scores after five and ten years, suggesting that EPs may 
assist predicting future disabilities of the patients and decisions in introducing 
treatments (Kallmann et al. 2006).   
 
Based on the advantages of electrophysiological examinations in patients, it would be 
reasonable also to examine animal models of MS electrophysiologically, not only in 
order to understand the mechanisms of neurological deficits, but also to apply this 
knowledge in therapeutic studies.  However, little has been done in this direction, and 
therefore this study is valuable as it aims to present electrophysiological features of the 
key stages (‘preinduction’, ‘predisease’, ‘peak disease’, ‘remission’ and ‘relapse’) of 
EAE induced in DA rats.  For this purpose, electrophysiological techniques were 
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optimised in naïve animals prior to application in animals with EAE.  Factors 
including the anaesthetic agent, stimulation frequency during recordings, temperature 
of the animal and placement of electrodes were optimised, as these elements affect the 
reliability and reproducibility of the recordings 
 
Anaesthetic agents affect the central nervous system characterised by analgesia and 
suppression of reflexes.  These agents act by depressing postsynaptic excitation, 
prolonging pre- or post-synaptic inhibition, and by blockade of ion channels (Dodd 
and Capranica 1992;Antkowiak 2001;Kopp et al. 2009).  Therefore it is anticipated 
that the configuration of recordings obtained under anaesthesia will be different from 
those taken without anaesthesia (i.e. under normal physiological conditions).  Also, the 
type of anaesthesia would be expected to influence the recordings depending on its 
mechanism of action.  Here in this study two different anaesthetic agents were used to 
test the excitability of motor neurons, as measured by the H reflex and F wave, and 
both recordings were better elicited under ketamine/xylazine than isoflurane (Figure 
3.6).  These findings accord well with the results reported from studies which 
demonstrated that volatile anaesthetics depress and/or abolish evoked potentials, while 
ketamine alone or in combination with xylazine had little or no influence on evoked 
potentials (Goss-Sampson and Kriss 1991;Chiba et al. 1998;Zandieh et al. 2003).  In 
addition, Zhou et al reported a suppression of spinal cord motor neuronal excitability 
using isoflurane anaesthesia in human (Zhou et al. 1997;Zhou et al. 1998) by 
measuring both H reflexes and F waves.  Similarly in animals, the amplitude of the F 
wave was also decreased in animals under isoflurane (Antognini and Carstens 1999).  
Studying the exact mechanism of depression under isoflurane is beyond the scope of 
this thesis, but this effect is unlikely to be due to effects at the neuromuscular junction 
or muscle, as the M responses were not influenced by the type of anaesthesia.  
Therefore, these findings suggest that ketamine/xylazine is a more appropriate agent 
for measuring motor neuronal excitability by monitoring H reflexes and F waves, 
compared with isoflurane.  Importantly, an appropriate stimulation frequency under 
anaesthesia should also be determined in order to obtain reproducible H reflexes and F 
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waves, as reflex attenuation occurs from post-activation depression (in this case the 
lowest frequency of 0.1Hz was used, Figure 3.6).  
 
The temperature at the site of recording (usually peripheral limbs) also affects 
electrophysiological recordings, and therefore in clinical settings, electrodiagnostic 
consultants generally aim to maintain the lower extremities of the patients between 
32 °C and 34°C during examinations.  In order to explore the effect of temperature on 
recordings of H reflexes and F waves, the hindlimbs were cooled down using ice bags.  
As a result, it was found that the latency, duration and amplitudes of both H reflexes 
and F waves increased as the temperature decreased (Figure 3.7, Figure 3.8).  This 
change of the action potential may occur due to the slowed opening and closing of the 
Na+ channel at low temperatures, as reported by Hodgkin et al (HODGKIN and KATZ 
1949).  Slow depolarisation of the axon results in reduced conduction velocity, and the 
combination of slow depolarisation and repolarisation causes longer channel opening 
time, therefore producing longer duration responses.  Also, larger response amplitude 
is as a result of more Na+ moving into the axon during prolonged opening of its 
channel, due to a larger depolarisation of the axon (Rutkove 2001).   
 
Placement of electrodes is also important in achieving reproducible data, as has been 
illustrated in Figure 3.12.  It shows that the response amplitude can be markedly 
increased or decreased by a movement of only 1mm of the recording electrode.  This 
implies that the proximity between the recording electrode and the nerve may affect 
the response amplitude, and therefore careful placing of the electrode is required in 
repeated consecutive analyses.   
 
In conclusion, these findings indicate the importance of optimising 
electrophysiological skills in naïve animals for achieving reliable data.  Based on these 
data, the developed techniques have been applied to the animals induced with EAE in 
order to interpret the recordings accurately.   
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6.2.  Characterisation of DA rats with rMOG-EAE to understand possible 
mechanisms underlying the relapses and remissions  
 
The aim of this study was to characterise DA rats induced with rMOG-EAE by using 
neurological, electrophysiological and histological techniques, at five key stages along 
the disease course, with the hope that these observations may indicate possible 
mechanisms responsible for the neurological deficits.  Neurological assessments were 
made by neurological scoring and examination of motor function of the limbs.  The 
weight and core temperature of these animals were also monitored in addition to 
record physiological changes.  Also, electrophysiological and histological assessments 
were performed in order to identify correlations between these factors and the severity 
of disease indicated by neurological scoring.   
 
6.2.1.  Neurological characterisation 
 
The results show that the neurological scores (Figure 4.2) and motor function of the 
limbs (Figure 4.5) was significantly decreased in animals with severe disease.  The 
examination of the motor function of the limbs which was measured by the inclined 
plane test, proved to be a reliable assessment as it was highly reproducible in naïve 
animals (Figure 4.4) and strongly correlated with the neurological scores in animals 
with EAE (Figure 4.6).  In addition, significant weight loss was also observed in 
animals present with severe neurological signs (Figure 4.3).  Weight loss in animals 
with EAE is a common feature of the disease, and some reports have suggested that 
the loss may be due to side effects from inflammatory mediators, suppression of 
appetite and ability to hydrate (Tracey et al. 1988;Strassmann et al. 1992;Encinas et al. 
2001).   
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Surprisingly, a significant negative correlation between the rectal temperature and 
neurological score of the animals with EAE was discovered (Figure 4.8).  The average 
core temperature of the animals at ‘peak disease (PD)’ and ‘relapse (REL)’ were  both 
below 35 °C, which indicates a hypothermic state (hypothermia is defined as a 
reduction of the core body temperature below 35°C (Fischbeck and Simon 1981).  This 
result is in line with the data from both rabbits and Lewis rats with EAE, where these 
animals also showed hypothermia correlating with severity of the disease (Pender and 
Sears 1984;Hansen and Pender 1989).  The authors claimed that hypothalamic lesion-
induced impairment of thermoregulation, and interruption of shivering pathways 
caused by demyelination/axonal degeneration could be the cause of hypothermia.  
Indeed cases of hypothermia have also been documented from MS patients with core 
temperatures ranging from 30°C to 35° (White et al. 1996;Linker et al. 2006;Weiss et 
al. 2009;Davis et al. 2010).  Most patients showing hypothermia typically had a long 
history of MS with severe clinical symptoms, and hypothermia was presented as acute, 
relapsing or even chronic.  A post-mortem pathological analysis (Linker et al. 2006) 
and MRI studies (White et al. 1996) revealed lesions around the hypothalamic area in 
these patients, but the exact relationship between thermo-dysregulation and 
neurological impairment is not yet clearly understood.  Therefore, further research on 
thermoeffector functions in animal models of MS may be required, such as by 
focusing on the functioning of shivering, sweating and heat dissipation.  In addition, 
studies on energy metabolism and distribution in these animals may also be valuable, 
and mitochondrial research in this regard could be helpful as it is recognised as a major 
source of heat production (Gambert and Ricquier 2007).  Indeed, mitochondrial 
dysfunction has been reported in MS lesions (Mahad et al. 2008;Witte et al. 2010), 
although the relationship between energy metabolism and temperature in patients is 
unknown.   
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6.2.2.  Electrophysiological and histological characterisation 
 
Previous electrophysiological studies on EAE concluded that demyelination occurring 
in both the CNS and PNS is the main cause of neurological deficits (described in 
Introduction section 1.3).  However, this explanation is less convincing to be applied 
in animals presenting transient neurological deficits, especially in the model used in 
this study which shows a transient first peak (named as ‘peak disease (PD)’, Figure 
4.2).  In this model, ‘peak disease (PD)’ occurred around day 18-20 post induction 
presenting severe neurological deficits, with recovery from some of the deficits around 
day 22-24 post induction (Figure 4.2).  This fast recovery is unlikely to be attributed to 
demyelination, as remyelination would take longer to occur (Smith et al. 1979).  In 
order to further understand the mechanisms responsible for the transient peak, recovery 
and relapse, longitudinal assessments were made at five key stages of EAE induced in 
DA rats to characterise the difference between each stage.  Several types of 
electrophysiological tests were used to examine neurological function within the CNS, 
and histological assessments were used to detect inflammation, axonal degeneration 
and demyelination.  In particular, the key role of inflammation in causing the deficits 
has been reported from clinical studies (Youl et al. 1991;Moreau et al. 1996;Bitsch et 
al. 2000), and indeed a marked role has also been confirmed in this study, by 
investigating the effect of systemic inflammation and iNOS inhibition in animals with 
EAE, which is further discussed in section 6.3.2. 
 
6.2.2.1.  Electrophysiological characteristics of the key stages of EAE 
 
 
Electrophysiological assessments were made in order to examine axonal conduction, 
motor neuronal excitability, synaptic transmission and synaptic activation of motor 
neurons within the central nervous system.  At the ‘peak disease (PD)’, axonal 
conduction (measured by SCAP, Figure 4.9.), synaptic transmission (CDP, Figure 
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4.11) and synaptic activation of motor neurons (SAM, Figure 4.12) were all 
significantly reduced, and these measures remained reduced during ‘remission (REM)’ 
and ‘relapse (REL)’.   
 
Conduction block is a well known cause of the deficits in EAE, shown by previous 
electrophysiological studies.  The impairment of axonal conduction has been 
classically attributed to the demyelination process (Waxman 1989;Smith and Hall 
2001;Wolswijk and Balesar 2003) or inflammatory mediators such as nitric oxide 
(NO) (Redford et al. 1997).  Indeed both demyelination and inflammatory factors were 
examined histologically and were detected in animals with EAE during the period 
presenting neurological deficits (Histopathological characteristics of EAE are further 
discussed in 6.2.2.2).   
 
The impairment of synaptic transmission in the grey matter has also been reported to 
be affected by inflammation in animals with EAE.  For example, a report from 
Centonze et al showed that synaptic degeneration and dendritic spine loss in animals 
with EAE were promoted by enhanced glutamate transmission under inflammatory 
conditions (Centonze et al. 2009).  In addition, an electrophysiological examination 
performed in animals with EAE in vitro, showed that AMPA-mediated spinal cord 
transmission deficits occurred from the onset of disease, which was sustained for two 
weeks (Hanak et al. 2004).  Within these two weeks, the animals underwent 
neurological remission, yet this recovery was not mirrored in the electrophysiological 
data, similar to the results described in this study.  Furthermore, synaptic changes of 
the motor neurons were also found in EAE,  where dendritic abnormalities of distal 
motor neurons (Zhu et al. 2003) and lumbosacral motor neurons (Bannerman et al. 
2005) were observed.  Also, Marques et al described synaptic retraction and 
reapposition of the motor neurons in EAE using ultrastructural techniques, and 
suggested that these changes could account for the paralysis observed during the peak 
of the disease (Marques et al. 2006). 
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However, motor neuronal excitability measured by the H reflex and F wave only 
showed a significant decrease at ‘relapse (REL)’ (Figure 4.10).  The reduction in 
amplitude of H reflex has also been reported in Lewis rats with MBP-EAE (Pender 
1989;Stanley and Pender 1991), and the reduction was attributed to demyelination in 
the PNS, especially in the dorsal and ventral roots and their entry/exit zones.  However, 
no pathology in the PNS was detected in animals induced with rMOG-EAE in this 
study, and the exact mechanism of the decreased excitability is not understood.  It is 
plausible that this decrease is due to the loss of motor neurons, as has been found in 
both actively and passively induced EAE (Vogt et al. 2009).  The authors claimed that 
a reduction of 47% to 74% of α-motor neurons was observed in animals with EAE 
compared to controls, and this could be due to neuronal damage caused by activated T 
cells and microglia.  Indeed activated microglia under inflammatory conditions have 
been reported to secrete inflammatory mediators such as TNFα, inducing motor neuron 
death (He et al. 2002;Sedel et al. 2004).  However, whether motor neuron loss occurs 
in animals with EAE from this study is not known. 
  
As described above, electrophysiological dysfunction which may contribute to the 
neurological deficits observed at ‘peak disease (PD)’ and ‘relapse (REL)’ was detected, 
but it was surprising that none of the measures showed an improvement upon 
‘remission (REM)’ from the neurological deficits.  This disassociation between 
electrophysiological finding and neurological presentation has also been documented 
in studies from MS patients, and these observations have lead some authors to suggest 
that evoked potentials may not be suitable for monitoring the course of MS (Matthews 
and Small 1979;Aminoff et al. 1984;Anderson et al. 1987).  In particular, Matthews et 
al found that abnormal somatosensory evoked potentials measured in patients with MS 
did not return to normal at remission, similar to the finding of this study.  This 
imbalance may occur if electrophysiological recordings at remission detected the 
progression of underlying disease.  It could also be influenced by unstable conduction 
properties of demyelinated axons with reduced safety factors,  which are easily 
affected by subtle environmental changes such as temperature (Davis 1970;Davis et al. 
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2010).  Indeed various physiological properties including temperature (Lenhardt 2010), 
heart rate, respiration, oxygen saturation and blood pressure are affected by anaesthetic 
agents (Karwacki et al. 2001), and any changes in these factors may influence the 
electrophysiological outcome.  Moreover, the effect of anesthetic agents on the 
nervous system per se should not be neglected, as these depress postsynaptic excitation 
or block ion channels, creating a totally different environment in contrast to the 
properties when awake.  Although it seems to be a difficult task, efforts to avoid the 
use of general anaesthesia in laboratory animals during recordings may become 
essential for the improvement in electrophysiological studies.  Although the 
electrophysiological mechanisms of remission in EAE have not been revealed from 
this study, inflammatory factors have been studied using histological techniques, and 
these have shed light on our understanding, as discussed below.   
 
6.2.2.2.  Histopathological characteristics of the key stages of EAE 
 
EAE has been the subject of several histological studies, but in this thesis the 
pathological hallmarks of MS, inflammation, demyelination and axonal degeneration, 
have been characterised and quantified at the five key stages of disease in DA rats 
induced with rMOG-EAE.   
 
A role for inflammation in causing neurological deficits has been suggested from 
clinical studies (Youl et al. 1991;Moreau et al. 1996;Bitsch et al. 2000), although the 
exact mechanisms remain unknown.  However, it has been described that 
inflammatory cells and their mediators may play a role in the pathogenesis of MS and 
its animal model EAE (Ford et al. 1995;Bruck et al. 1995;Raivich and Banati 2004).  
In particular, brain- resident microglia and hematogenous macrophages are 
representative inflammatory cells which are involved in the pathology, by presenting 
antigen to T lymphocytes after being recruited to sites of inflammation, and 
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synthesising molecules such as cytokines, chemokines and reactive oxygen radicals 
which could exert damaging effects on the surrounding tissue (Raivich and Banati 
2004).  Indeed, the role of macrophages and microglia has been implicated in a number 
of earlier studies using various models of EAE, where these cells were detected in 
accordance with the expression of disease (Berger et al. 1997;Brown and Sawchenko 
2007;Rasmussen et al. 2007).  Accordingly, it was found in this study that the activity 
of macrophages/microglia shown by ED1 labeling was significantly increased at the 
‘peak disease (PD)’ and ‘relapse (REL)’ in animals with EAE (Figure 4.14), and a 
positive correlation between the ED1 labeling and neurological severity was shown 
(Figure 4.16).  The increased labeling at the two peaks could be due to the proliferation 
of resident microglia or recruitment of blood borne macrophages, as has also been 
suggested from a study by Bauer et al  using Lewis rats induced with chronic relapsing 
EAE (Bauer et al. 1994).  Noticeably, these authors reported that the pattern of ED1 
labeling in the brain of the animals was different between the first peak and relapse. 
They described that at the first peak, ED1 labeling was confined in or around the 
lesions, but at relapse, the labeling affected a larger area including fields further away 
from the lesions, suggesting that newly recruited positive macrophages may have 
infiltrated the brain.  A difference in the pattern of ED1 labeling between the two 
peaks was also found in this study (Figure 4.15), where the cells were confined in 
subpial and perivascular regions at ‘peak disease (PD)’ but were concentrated in the 
white matter at ‘relapse (REL)’.  These findings suggest that the phagocytic cells may 
behave differently at the two peaks, and may contribute to pathology via different 
mechanisms.  However, so far the proportion of these cells within the ED1 positive 
population and their interaction is not known from this study, nor from any others.  
Therefore, further investigation is required to find out the composition of these cells 
and also to understand their role in the pathogenesis of EAE. 
 
This study has especially explored a potential role for another important inflammatory 
factor, inducible nitric oxide synthase (iNOS), which can be expressed by 
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macrophages, microglia or neutrophils under inflammatory conditions.  iNOS is 
known to produce large amounts of NO, and it was found to be exclusively expressed 
at the ‘peak disease (PD)’ of EAE (Figure 4.17 and Figure 4.18) in this study.  The 
presence of iNOS produced by macrophages has been demonstrated in other studies 
using EAE animals, and the iNOS expression was found to correlate with the disease 
activity (Van Dam et al. 1995;Cross et al. 1996;Zhao et al. 1996;Brenner et al. 1997).  
In both the published and current study, iNOS expression was mostly perivascular, and 
it has been suggested that the perivascular iNOS positive cells may contribute to 
damage of the blood-brain barrier, and other CNS tissues.  The current findings 
suggest that ED1 positive and iNOS positive macrophages or microglia may be 
responsible for the neurological deficits at the ‘peak disease (PD)’.  The possible role 
of NO was specifically explored in this thesis by administrating an iNOS inhibitor 
(1400W) in the animals with EAE to block the production of NO and its detrimental 
effect.  The results are discussed in section 6.3.2. 
 
The amount of demyelination and axonal degeneration was quantified in the spinal 
cords of animals at each stage of EAE.  The pathology of the white matter affected by 
either demyelination or degeneration was initially detected at the first peak of disease 
(PD, 16.5%) and it further increased at ‘relapse (REL)’ to 58.9% (Figure 4.19, Figure 
4.20).  Increasing white matter pathology has also been documented in relapsing-
remitting EAE models induced in Biozzi ABH mice with spinal cord homogenate 
(Hampton et al. 2008;Jackson et al. 2009), and in DA rats with rMOG (Papadopoulos 
et al. 2006) as the disease progressed.  However, in this thesis, the dorsal columns of 
the same animals were separately assessed, in order to find out whether there was a 
correlation with axonal conduction measured by sensory compound action potentials 
(SCAP).  Results show that the proportion of axonal degeneration in the dorsal column 
was more than 50% at both ‘peak disease (PD)’ and ‘relapse (REL)’ (Figure 4.21 (b)), 
but only approximately 6% was present at ‘remission (REM)’.  This unexpectedly 
small area of axonal degeneration found at ‘remission (REM)’ is an unexplained 
observation in the current study, as it is implausible that the observed animals at ‘peak 
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disease (PD)’ would lose any evidence of the pathology suspected to have caused the 
severe deficits observed earlier in these particular animals.  The findings need further 
study in a larger cohort of animals, but this is beyond the scope of this thesis.  A 
contributing factor might be the fact that the lesions of EAE are widespread within the 
CNS, so there is a chance of overlooking the pathology that may be present at other 
locations, hence an investigation exploring the cord longitudinally may provide the 
explanation.   
 
6.2.3.  Possible mechanisms underlying the first peak and relapse in rMOG-
EAE induced in DA rats 
 
In the present study the main differences in electrophysiological and histological 
features were found between the first peak (‘peak disease’) and the relapse in animals 
with EAE.  At the first peak, axonal conduction, synaptic transmission, and synaptic 
activation of motor neurons were significantly impaired.  However, motor neuronal 
excitability was not affected at this stage but showed significant decrease measured by 
the H reflex and F wave at relapse.  The exact mechanisms of how these 
electrophysiological changes occur in pathological animals is not clear from this study, 
but several studies have reported that pathological events such as demyelination or 
inflammation can be the cause of conduction block (Waxman 1989;Redford et al. 
1997;Smith and Hall 2001;Wolswijk and Balesar 2003) and synaptic dysfunction 
(Hanak et al. 2004;Centonze et al. 2009).  Roles for NO for contributing to 
neurological deficits seem especially likely from the present results, and this agent is 
known to be a potent cause of conduction block, especially in demyelinated axons 
(Redford et al. 1997).  The presence of actively phagocytic ED1 positive cells and 
demyelination were also found in the present study within the spinal cord of animals, 
which may also have contributed to the presentation of neurological deficits.  However, 
it was also noted that the localisation of ED1 expressing cells within the spinal cord 
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was different between the two stages, and the expression of iNOS was exclusively at 
the first peak and not at relapse.   
 
These findings suggest that different pathological events arising through different 
mechanisms could be responsible for the neurological deficits present at the two peaks, 
although the expression of neurological deficits was similar.  More importantly, 
present data are valuable for understanding the characteristics of the two peaks and 
applying these findings for developing therapies for MS.  For example, in the current 
study, the administration time of iNOS inhibitor (1400W) was selected depending on 
the exclusive expression of iNOS at the first peak of EAE, therefore increasing the 
efficacy of the treatment (further discussed in later section 6.3.2.).  In addition, it has 
been described for the first time from this study that the significant reduction of motor 
neuronal excitability (determined using electrophysiological techniques) occurs only at 
relapse.  Although motor neuronal loss has been reported in MS (Vogt et al. 2009), it is 
not yet known whether there is a tendency for increased motor neuronal pathology in 
patients with progressive phase of MS than in patients during their acute phases, as 
seen in our model of MS.  As it is difficult to obtain tissues from acute patients for 
histological comparison with patients with progressive disease, the value of research 
on relapsing remitting EAE exploring the acute and progressive phase is clear.  Indeed 
a study on rMOG-EAE induced in DA rats focusing on the immunobiology of the 
disease revealed that the first peak may be driven by CD4+ Th1 lymphocyte-induced 
inflammation, but relapse may be due to demyelination caused by MOG-specific 
antibodies (Schubart A 2001).  Clinical data also support this interpretation by 
reporting increased serum levels of anti MOG antibodies in patients at their relapse 
(Angelucci et al. 2005).  On the basis of these observations, it would be reasonable to 
try to develop a therapy to eliminate circulating MOG antibodies.  In conclusion, 
further electrophysiological and histological profiling of animals with EAE will be 
required not only to understand the mechanisms of deficits occurring at both the acute 
and relapse phase, but also to develop an effective treatment. 
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6.3.  Modulation of inflammatory factors affects the disease course of EAE 
 
6.3.1.  LPS injection exacerbates the disease course 
 
In this study, systemic inflammation was induced in the animals with EAE during 
remission by intravenous injection of a bacterial endotoxin, lipopolysaccharide (LPS), 
in order to explore whether and how LPS injection exacerbates the disease, using 
neurological and electrophysiological techniques.  Indeed there has been clear 
evidence in patients with MS that infection-derived inflammation may cause relapses 
(Edwards et al. 1998;Confavreux 2002;Buljevac et al. 2002), and sequence similarity 
between microbial and self antigens has been suggested to induce autoimmunity which 
may explain these relapses.  However, so far no specific pathogen has been identified, 
and the exact mechanisms are poorly understood.   
 
In the present study, the neurological scores of animals which were injected with LPS 
had significantly increased after 3.5 hours post injection in association with decreased 
motor function of the limbs (Figure 5.1 (a), (b)).  These findings bear similarities to a 
study from Nogai et al, where the authors observed relapses in SJL mice induced with 
MBP-EAE after systemic injection of LPS during remission (Nogai et al. 2005).  The 
mean neurological score of these mice at their relapse was 2.5 scores higher than the 
first episode of EAE.  This exacerbation was attributed to antigen-independent 
‘bystander activation’ of T cells, supported by in vitro observations of activated Th 
lymphocytes in the absence of TCR mediated signals.  Also another study 
demonstrated that a systemic inflammatory challenge by LPS injection reactivated the 
quiescent lesions in the brain of Lewis rats induced with MOG-EAE, using multimodal 
MRI techniques and histology (Serres et al. 2009).  Noticeably, the authors described 
that there was an increase in the number of newly recruited lymphocytes and 
macrophages/microglia at the lesion sites, following the inflammatory insult.  LPS-
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induced activation of peripheral macrophages was also described earlier in Australian 
albino rats, and these macrophages were suggested to cause neurological impairment 
evidenced by experiments using macrophage inhibitors (Brown et al. 1999).  Thus, 
exploring whether active macrophages/microglia also reappear in animals during LPS-
induced exacerbation following the first appearance at ‘peak disease (PD)’ (Figure 
4.14), may be helpful in understanding the pathological role of these cells in causing 
relapse.   
 
Surprisingly, no significant change of electrophysiological measure was detected at the 
peak of LPS-induced transient exacerbations (Figure 5.2).  This finding is in contrast 
to an electrophysiological study performed by Brown et al, using Australian albino 
Wistar rats injected with LPS, both intraperitoneally and intravenously (Brown et al. 
1999).  These rats also exhibited a transient neurological dysfunction after the injection, 
but electrophysiological analysis revealed that the impairment was associated with a 
transient conduction block in the sciatic nerve, or impaired function of the 
neuromuscular junction.  As discussed earlier, the reason for the disassociation 
between the neurological presentation and electrophysiological data found in the 
current study is not fully understood, but it may be due to unstable conduction 
properties in axons with reduced safety factors, or the side effects from anaesthesia per 
se during electrophysiological recordings.   
 
So far from the results described in this study, the exact mechanisms underlying the 
LPS-induced relapse in animals with EAE remain unknown.  However, a study from 
Moreau et al provided good evidence supporting the role for cytokines in causing 
transient worsening of symptoms in patients with MS using CAMPATH-1H, a drug 
which depletes lymphocytes and some monocytes (Moreau et al. 1996).  In most of the 
patients, symptoms appeared in accordance with the administration of CAMPATH-1H 
associated with an increase in the level of cytokines.  The exacerbation did not occur in 
patients treated with an anti-inflammatory drug, which blocked the surge of cytokines.  
The authors suggested that cytokines such as TNF-α and IFN-γ may contribute to 
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production of symptoms in these patients, by affecting conduction.  It is plausible that 
the exacerbation reported in this thesis may have also occurred through a similar 
mechanism, as reports have shown that systemic injection of LPS in animals also 
induces production of cytokines such as TNF-α and IFN- γ (Varma et al. 2002;Qin et 
al. 2007).   
 
It is not yet known why cytokines might cause relapses, but hypoxia in spinal cords of 
animals with EAE has been investigated as a potential cause of neurological 
dysfunction in our laboratory, evidenced by histological data and oxygen electrode 
recordings (unpublished data).  In this regard, it is plausible that the spinal cord may 
have also become hypoxic in response to systemic inflammation by LPS injection, due 
to hyper-metabolism and limitation in the amount of oxygen the blood can supply to 
the tissue.  It is therefore possible that anaesthesia-induced suppression of 
physiological activity, coupled with non-physiological stimulation frequencies (no 
greater than 1Hz) used in the current study during recordings under anaesthesia, hence 
providing reduced electrical activity, may alleviate hypoxia in animals with EAE, by 
reducing the demand for ATP.  If so, the alleviation of hypoxia may have relieved 
conduction deficits due to this cause, meaning that no conduction deficits were present 
at the time of recording.  However, whether hypoxia is induced by systemic LPS 
injections needs to be determined. 
 
It is also noticeable that a decrease of core temperature was observed at the peak of 
exacerbation in association with neurological impairment, in rats which received LPS 
(Figure 5.1 (c)).  This decrease of temperature was reminiscent of hypothermia 
observed at the ‘peak disease (PD)’ in animals with EAE (Figure 4.7), and whether a 
common mechanism causing the temperature decrease applies to both cases is possible.  
It has been reported that hypothermia was induced in a dose dependent, monophasic 
manner, which was maximised at 2 hours post intravenous injection of LPS in mice 
(Greer and Rietschel 1978).  In this report the mice lost a maximum of 2°C when they 
were injected with the highest dose of LPS (100µg per mice).  Also, Arkarsu et al 
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reported hypothermia in Wistar albino rats injected with LPS (250µg/kg) measured by 
a temperature transmitter implanted into the peritoneal cavity (Akarsu and Mamuk 
2007).  The authors described that the loss of temperature in these animals was in 
association with the increased serum level of TNF-α, suggesting that antipyretic 
cytokines may be involved in the generation of hypothermia.  Whether the level of 
cytokines such as TNF-α is elevated after the injection of LPS in animals used in this 
study remains to be determined. 
 
In conclusion, these results show that systemic inflammation can cause transient 
neurological deficits in animals with EAE, and these animals may serve as a model of 
MS with brief relapses.  For example, this model may be useful for studying the 
mechanisms of transient worsening of symptoms observed in the CAMPATH-1H trial 
(Moreau et al. 1996).  Further efforts are required to identify potential factors 
contributing to the exacerbation, such as the involvement of inflammatory cells and 
their soluble mediators.  Also, understanding the relationship between the neurological 
deficits and physiological properties of the animal such as body temperature and tissue 
oxygen concentration will be beneficial in revealing the exact mechanisms of relapse.  
Investigation to develop strategies for preventing or treating infectious diseases to 
prevent relapse in MS should also be pursued.  
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 6.3.2.  iNOS inhibition ameliorates the disease course and may be useful in 
therapy for MS 
 
Together with evidence from several laboratories reporting a positive correlation 
between iNOS and disease activity in animals with EAE (Van Dam et al. 1995;Cross 
et al. 1996;Zhao et al. 1996;Brenner et al. 1997), the exclusive expression of iNOS at 
peak disease (PD) in animals in this study (Figure 4.17, Figure 4.18) supports a 
pathological role of NO in EAE.  Based on these data, a highly selective iNOS 
inhibitor, 1400W, was administered to animals with EAE at the onset of disease, in 
order to determine whether iNOS inhibition ameliorates the disease, as assessed by 
neurological, electrophysiological and histological techniques.  Animals treated with 
1400W exhibited a significantly reduced severity of neurological deficit during the 
peak of disease (Figure 5.3), and the average of neurological scores at peak was also 
significantly lower than controls (Figure 5.4).  Furthermore, electrophysiological 
examination showed that sensory compound action potentials (SCAP) obtained from 
animals treated with 1400W were significantly larger than in controls, indicating that 
many more functioning axons survived in treated animals (Figure 5.5).  The larger 
SCAP in the treated group correlated with the histological findings of the dorsal 
columns, as there were more surviving, demyelinated axons in animals treated with 
1400W than in controls.  Altogether these findings suggest that NO produced by iNOS 
may contribute to the loss of function, and to axonal degeneration, and that judiciously 
timed iNOS inhibition may be beneficial in the therapy of MS. 
 
These findings are in agreement with studies that suggest a role for NO in tissue 
damage.  NO has been reported to be cytotoxic and destructive to tissues for many 
reasons such as the fact that it up-regulates the production of TNF-α in macrophages 
(Deakin et al. 1995).  Also, NO, being a free reactive radical in its own right, has been 
demonstrated to damage oligodendrocytes in EAE (Merrill et al. 1993;Koprowski et al. 
1993).  NO also binds to superoxide anion (O2•-) to generate peroxynitrite anion 
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(ONOO-), which is an even stronger oxidant than either NO or O2•- (Beckman et al. 
1990).  More importantly, several studies have shown that inhibition of NOS in 
animals with EAE ameliorated the severity of disease, re-affirming a deleterious role 
for NO (Cross et al. 1994;Zhao et al. 1996;Brenner et al. 1997).  However, 
contradicting outcomes from studies using NOS inhibitors in EAE have also been 
reported, indicating that NO can have a protective role under some circumstances 
(Zielasek et al. 1995;Ruuls et al. 1996;Fenyk-Melody et al. 1998).  Based on these 
varied results it has been suggested that different methods of EAE induction, type of 
inhibitors, different administration routes or dosing schedules of the inhibitors may 
influence the outcome.  Different strains or genders of animals may also affect the data, 
as the amount of NO produced varies accordingly (Ding et al. 1997;Cowden et al. 
1998).  Taking these factors into consideration, it is worth comparing the present data 
with results from a study using a similar protocol.  Thus Kahl et al used DA rats 
induced with rMOG-EAE which showed a relapsing disease form and administered a 
relatively selective iNOS inhibitor, aminoguanidine (AG) (Kahl et al. 2003).  AG was 
administered at two time points in order to understand the role of NO during the 
induction and effector phases of EAE.  The animals were found to have a more severe 
disease course when they received the treatment early during the induction phase 
(beginning on the day after induction), but no significant effect was observed when the 
administration started after the onset of disease.  These results supported a protective 
role of NO in the pathogenesis of EAE (in contrast to the present study, which showed 
protection after disease onset) and also pointed to a complex role of NO in different 
phases of disease.  There are two obvious differences between the study by Kahl et al 
and the present study, which may have caused the contradictory outcomes.  Firstly, 
AG is not as specific for iNOS as is 1400W, and hence the use of this drug in animals 
may have caused an inhibition of the constitutively expressed endothelial NOS (eNOS) 
or neuronal NOS (nNOS) (Ou and Wolff 1993;Laszlo et al. 1995).  In contrast, 1400W 
is a highly selective inhibitor of iNOS over the other forms of NOS (Garvey et al. 
1997).  Secondly, the route of administration was different which may have affected 
the pharmacokinetics of the drug, influencing its time of action.  However, the exact 
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reasons which explain the contradictory results are not yet understood, and further 
studies should be designed not only to understand this difference, but also to 
understand the exact role of NO in the disease course of EAE.  
 
Two important goals in assessing the role of NO in EAE by administrating NOS 
inhibitors are, firstly, to determine the type of NOS present within the tissue, and also 
how expression changes during the disease course.  This information allows the most 
specific inhibitor to be administered at the most opportune time.  The second goal is to 
achieve reliable methods to examine the efficacy of the drug, including neurological, 
electrophysiological, and histological methods.  In the present study, the time frame of 
administering the iNOS inhibitor (1400W) was prescribed by the expression of iNOS 
exclusively at the peak disease (PD), which also defined our strategy of administration 
of the 1400W at the onset of disease expression.  To assess the efficacy of the drug, all 
animals in the trial were examined not only by the functional analysis of the axons 
measured by sensory compound action potential (SCAP) recordings, but also by 
histological examinations of the corresponding axons in the dorsal column.  These data 
combined have provided a more complete explanation for the amelioration of 
neurological deficits observed in animals administered with 1400W, by presenting 
both physiological and pathological information.  So far, only one previous study has 
aimed to explore the electrophysiological outcome of NOS inhibition in animals with 
EAE and EAN (experimental autoimmune neuritis, an animal model of Guillain-Barré 
syndrome) in association with histological examinations (Zielasek et al. 1995).  There 
were no significant clinical or electrophysiological changes found in the drug-treated 
animals with EAE, but the compound muscle action potentials measured from the 
sciatic nerve remained intact in EAN animals treated with NMMA which was 
attributed to the decreased numbers of cellular infiltrates in the sciatic nerve compared 
to controls.  Therefore, electrophysiological examinations can be helpful in assessing 
the efficacy of the NOS inhibitors, although it has not been successful in revealing the 
cause of the transient peak, remission and relapse in animals with EAE in this study.   
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In conclusion, the data presented in the current study are supportive of a deleterious 
role of NO in DA rats with rMOG-EAE, in which NO impairs function, and promotes 
degeneration.  It remains to be determined whether the current findings also apply in 
MS, and to which stages of lesion development.  iNOS expression in MS does not only 
occur in the active inflammatory lesions, but it is also widely expressed throughout the 
CNS in progressive disease (Smith and Lassmann 2002;Alastair Compston et al. 2005) 
raising the intriguing possibility that NO may contribute to the ‘slow burn’ of axonal 
degeneration in progressive disease, as well as the substantial, synchronous 
degeneration that characterises acute relapses. 
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6.3.3.  Conclusive remarks 
 
The aim of this thesis was to explore the mechanisms of relapse and remission in EAE 
using neurological, electrophysiological, and histological techniques.  The results have 
been unexpected in that, so far, none of the electrophysiological measures have 
correlated with the recovery from the neurological deficits of the animals, although 
some electrophysiological deficits were decreased at the first peak of deficit, and at 
relapse.  To understand this unexplained finding, it is required to further explore the 
potential effects from some factors which may affect the physiology of the animals 
with EAE, such as anaesthetic agents or hypoxia.  However, current data revealed that 
modulation of inflammatory factors significantly affected the severity and pathology 
of the disease course of EAE.  Systemic inflammation activated by an injection of 
lipopolysaccharide (LPS) into animals with EAE at their remission, induced a transient 
exacerbation of disease.  This finding suggests that inflammation may play a 
significant role in the pathology of MS, and that these animals may serve as a model of 
MS with brief relapses.  Importantly, inhibition of an inducible nitric oxide synthase 
(iNOS) using a selective iNOS inhibitor, 1400W, at the onset of the disease in animals 
with EAE significantly ameliorated the neurological deficits.  These animals were also 
present with improved axonal conduction measured by sensory compound action 
potential (SCAP) compared to controls, which may be due to the protection of axonal 
degeneration as shown by histological observations.  These data suggest that duly 
timed inhibition of iNOS may be therapeutic for patients with MS.  However, further 
accurately designed experiments are required to confirm this finding using other 
models of MS to understand the contradicting results reported from NOS inhibition in 
animals with EAE.    
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6.4.  Future directions 
 
The present work shows that inflammation may play a significant role in the 
neurological deficits associated with MS, and that the inhibition of iNOS can be 
beneficial in alleviating these deficits.  However in order to apply iNOS inhibition as a 
therapy for the patients, a few points remain to be validated using the animal model. 
 
Firstly, sampling error must be minimised which occurs inevitably when selecting 
animals for analysis at different stages along the disease course.  Basically, most EAE 
studies are based on the assumption that all the animals in the study go through a 
similar disease course.  However, during this study, it was noticed that some animals 
developed neurological deficits earlier than others (showing first sign of deficits earlier 
than day 11 post-induction), and that these were more likely to acquire a primary 
progressive disease course with more severe deficits (paralysed limbs).  In contrast, the 
majority of the animals which showed the first sign of deficit around day 13 to 15 
post-induction, was more likely to present a relapsing-remitting disease course as has 
been illustrated in Figure 4.1.  In the present study, naturally, animals developing the 
disease earlier than others were selected for the analysis of ‘peak disease’, and 
therefore there is a possibility that these animals may have developed a primary 
progressive disease course, when other animals selected for ‘remission’ and ‘relapse’ 
developed a relapsing-remitting disease course.  In this case, animals in different 
groups may have shown different pathology according to their disease progression, 
hence introducing sampling error in histological analysis.  Therefore in the future 
studies, it is reasonable to minimise the sampling error by avoiding animals with an 
atypical disease course or expression of deficits.  Also, it is important to take into 
account the heterogeneous characteristics when interpreting the data obtained from 
these animals. 
 
Secondly, further research is required to understand the exact mechanisms of NO-
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induced damage revealed by the present study.  It was found that the iNOS inhibitor-
treated animals showed significantly lower neurological scores compared to controls, 
and the difference in scores between the two groups was maximised by day 2 post-
administration (Figure 5.3).  Further histological analysis aimed at this time point 
measuring the levels of iNOS expression will confirm the mechanism of action and 
efficacy of the inhibitor.  Also, in order to measure the degree of damage, measuring 
nitrotyrosine production, axonal degeneration or inflammatory mediators such as 
cytokines may be useful.  In addition, observations at an extended time point after 
administrating the iNOS inhibitor may reveal the effect of drug on the overall disease 
course of EAE.  In the present study, the effect of the drug on the progression of the 
disease was not determined due to the termination of study at day seven post-
administration of drug.  Exploring whether iNOS inhibition also prevents relapse in 
these animals and preserves axonal function in the later progressive stage of the 
disease would be valuable for understanding the therapeutic value of this drug in 
progressive inflammatory neurological diseases.   
 
Furthermore, administering the iNOS inhibitor in another type of relapsing-remitting 
model of EAE may enhance our understanding of the exact role of NO in the disease, 
by comparing the results with the present study.  Thus LEW.1AV1 rats induced with 
MOG-EAE can be used as a relapsing-remitting model as these animals express a clear 
first peak and relapse (Matsumoto et al. 2009).  Importantly, the time frame of iNOS 
expression should be primarily determined within these animals to ensure the effective 
delivery of the drug.   
 
In conclusion, although there are many hurdles which must be overcome for iNOS 
inhibition to be applied to the clinic, the potential seems to be great based on the 
findings from the present work and other studies supporting the damaging role of NO.  
It is particularly notable that iNOS inhibition could prove to be protective against 
axonal damage, as degeneration of axons is associated with permanent disability in 
patients with MS. 
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